|
1
|
Eren A, Varol M, Unal R, Altan F. Exploring Urtica dioica L. as a Promising Alternative Therapy for Obesity-Related Breast Cancer: Insights from Molecular Mechanisms and Bioinformatic Analysis. PLANT FOODS FOR HUMAN NUTRITION (DORDRECHT, NETHERLANDS) 2025; 80:102. [PMID: 40153121 PMCID: PMC11953088 DOI: 10.1007/s11130-025-01341-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 03/06/2025] [Indexed: 03/30/2025]
Abstract
Obesity and obesity-related breast cancer are major health problems that require alternative treatment strategies. Urtica dioica L. (U. dioica) stands out as a potential therapeutic candidate with its anti-oxidant, anti-cancer and lipid-lowering properties. In this study, the molecular effects of U. dioica were investigated by gene expression analysis and molecular docking methods. U. dioica significantly suppressed the expression of Brca1, Brca2, Fas, Lpl, Dgat1 and Mcp1 genes, resulting in significant changes in lipid metabolism, cancer susceptibility and inflammation. Molecular docking analyses showed that U. dioica components have strong binding affinities with target proteins. In particular, the interactions between Dgat1-Isorhamnetin rutinoside (-10.3 kcal/mol), Fas-Quercetin acetyl rutinoside (-10.3 kcal/mol), Lpl-Apigenin hexoside (-9.2 kcal/mol) and Mcp1-Quercetin acetyl rutinoside (-8.6 kcal/mol) were notable. In vitro and in silico analyses supported each other, revealing the effects of U. dioica in gene expression regulation and the potential for its constituents to interact with proteins. These findings indicate that U. dioica may be a promising alternative therapeutic agent in the treatment of obesity and obesity-related breast cancer and emphasize that its efficacy should be confirmed by clinical trials.
Collapse
Affiliation(s)
- Ayla Eren
- Department of Molecular Biology and Genetics, Faculty of Science, Muğla Sıtkı Koçman University, 48000, Kötekli, Muğla, Turkey
- Molecular Biology-Genetics and Biotechnology Program, Istanbul Technical University, 34469, Maslak, Istanbul, Turkey
| | - Mehmet Varol
- Department of Molecular Biology and Genetics, Faculty of Science, Muğla Sıtkı Koçman University, 48000, Kötekli, Muğla, Turkey
| | - Resat Unal
- Department of Molecular Biology and Genetics, Faculty of Science, Muğla Sıtkı Koçman University, 48000, Kötekli, Muğla, Turkey
| | - Filiz Altan
- Department of Molecular Biology and Genetics, Faculty of Science, Muğla Sıtkı Koçman University, 48000, Kötekli, Muğla, Turkey.
| |
Collapse
|
|
2
|
Mabrouk RR, Mahdy HA, Abdallah AE, Celik I, Abdelsalam Ouf AM, Alamoudi MK, Alnami A, Al Ward MMS, Mehany AB, El-Zahabi MA. Novel triazoloquinazoline derivatives as VEGFR inhibitors: synthesis, cytotoxic evaluation and in silico studies. Future Med Chem 2025; 17:529-541. [PMID: 39995350 PMCID: PMC11901504 DOI: 10.1080/17568919.2025.2468146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2024] [Accepted: 02/07/2025] [Indexed: 02/26/2025] Open
Abstract
BACKGROUND New triazoloquinazoline derivatives were synthesized to explore their cytotoxic activity on various cancer cell lines, prompted by the need for effective anticancer agents. RESEARCH DESIGN AND METHODS All synthesized compounds were confirmed by spectroscopic methods and tested in vitro for their inhibitory activities against hepatocellular carcinoma (HepG-2), breast cancer (MCF-7), and prostate cancer (PC3) cell lines. Ten compounds were tested in vitro to explore their inhibitory activity against the VEGFR-2. Additionally, various studies were investigated for the most active compound 6, including cell cycle analysis, apoptotic activity assessment, effect on gene expression, safety profiling, molecular docking, MD simulation, and ADMET analysis. RESULTS Compounds 3a, 3c, and 6 exhibited higher cytotoxic activity against MCF-7 than doxorubicin. Compound 6 was most potent, arresting the cell cycle at G1 phase and showing proapoptotic action. It significantly inhibited VEGFR-2 and altered gene expression, promoting BAX, P21, and P53 while downregulating BCL-2. Docking and MD simulations indicated stable interaction with VEGFR-2, safety, and ADMET profiles suggested favorable drug-likeness and safety. CONCLUSIONS Compound 6 has shown promising anticancer potential, particularly against breast cancer, but further research is needed to confirm these findings and address long-term safety.
Collapse
Affiliation(s)
- Reda R. Mabrouk
- Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt
- Directorate of Health Affairs in Buhaira-Clinical Research Department, Ministry of Health and Population, Damanhour, Egypt
| | - Hazem A. Mahdy
- Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt
| | - Abdallah E. Abdallah
- Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt
| | - Ismail Celik
- Pharmaceutical Chemistry Department, Faculty of Pharmacy, Erciyes University, Kayseri, Turkey
| | | | - Mariam K. Alamoudi
- Department of Pharmacology, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia
| | - Aisha Alnami
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
- Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Maged Mohammed Saleh Al Ward
- Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt
- Medicinal Chemistry Department, Faculty of Pharmacy, Al Razi University, Sana’a, Yemen
| | - Ahmed B.M. Mehany
- Zoology Department, Faculty of Science (Boys), Al-Azhar University, Cairo, Egypt
| | - Mohamed Ayman El-Zahabi
- Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt
| |
Collapse
|
|
3
|
Gheidari D, Mehrdad M, Bayat M. Novel indenopyrrol-4-one derivatives as potent BRDT inhibitors: synthesis, molecular docking, drug-likeness, ADMET, and DFT studies. J Biomol Struct Dyn 2024; 42:7860-7873. [PMID: 37528682 DOI: 10.1080/07391102.2023.2242502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Accepted: 07/23/2023] [Indexed: 08/03/2023]
Abstract
We synthesized new, structurally distinct series of indeno[1,2-b]pyrrol-4(1H)-ones. Effective derivatives were found by in silico screening, and our studies revealed that compound 5h exhibited good binding energies for inhibition of BRDT. In addition, DFT studies were carried out by means of the B3LYP/6-3lG basis set in the gas phase to investigate the conformation of protein-ligand interactions. The results of the investigation suggest that these compounds could be considered novel BRDT inhibitors. The pharmacokinetic and drug-like properties of the new indenopyrrol-4(1H)-one derivatives exhibited that these compounds could be represented as potential candidates for further development into anticancer-like agents. Additionally, based on the optimised structures, the optimum geometry for each of the selected molecules was developed. Then, the estimated and the experimentally determined IR vibrational frequencies for each compound were compared. The results of this comparison showed that the theoretical and experimental data were in excellent agreement, which could support the reliability of the experimental analytical data and the applicability of the mathematical model.Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
- Davood Gheidari
- Department of Chemistry, Faculty of Science, University of Guilan, Rasht, Iran
| | - Morteza Mehrdad
- Department of Chemistry, Faculty of Science, University of Guilan, Rasht, Iran
| | - Mohammad Bayat
- Department of Chemistry, Faculty of Science, Imam Khomeini International University, Qazvin, Iran
| |
Collapse
|
|
4
|
Lim HW, Passeron T, Goh CL, Kang HY, Ly F, Morita A, Ocampo-Candiani J, Puig S, Schalka S, Wei L, Demessant AL, Le Floc'h C, Kerob D, Dreno B, Krutmann J. Evaluating the Frequency of Mole Checks by a Dermatologist and Correlated Variables in a Global Survey across 17 Countries: HELIOS Project. Acta Derm Venereol 2024; 104:adv40929. [PMID: 39177162 PMCID: PMC11358839 DOI: 10.2340/actadv.v104.40929] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2024] [Accepted: 07/03/2024] [Indexed: 08/24/2024] Open
Abstract
Secondary prevention of skin cancer consists in early detection of malignant lesions through patients' mole self-examination and medical examination. The objective of this study was to assess the self-reported frequency of mole examination in a large, representative sample of the adult general population of 17 countries from all continents. Of a total of 17,001 participants, 4.8% had their moles checked by a dermatologist more than once a year, 11.3% once a year, 8.4% every 2-3 years, 12.4% once in a while, 10.3% once in lifetime, and 52.6% of participants had never performed a mole examination. Egypt was the country with the highest prevalence of people who performed a moles check more than once a year (15.9%), followed by Brazil and the USA. A higher frequency of mole checks was associated with sex (man vs woman), higher education, higher income, fair phototype, history of skin cancer, medical insurance, and sun-protective behaviours. Despite recommendations by health providers, it appears that the frequency of mole checks in the general population is still low. It is necessary for dermatologists to keep informing at-risk populations about the importance of moles check, with particular care regarding categories that less frequently adhere to secondary prevention measures.
Collapse
Affiliation(s)
| | - Thierry Passeron
- 2. Department of Dermatology, Côte d'Azur University, Nice University Hospital Center, Nice, France; INSERM U1065, C3M, Côte d'Azur University, Nice, France
| | | | - Hee Young Kang
- Department of Dermatology, Ajou University School of Medicine, Suwon, South Korea
| | - Fatimata Ly
- Department of Dermatology, Cheikh Anta Diop Dakar University, EPS Institute of Social Hygiene, Dakar, Senegal
| | - Akimichi Morita
- Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
| | - Jorge Ocampo-Candiani
- Universidad Autonoma de Nuevo León, Facultad de Medicina, University Hospital, "Dr. Jose E. González", Monterrey, Mexico
| | - Susana Puig
- Dermatology Department, Hospital Clinic de Barcelona, Barcelona University, Barcelona, Spain
| | - Sergio Schalka
- Medecin Skin Research Center and Biochemistry Department, Chemistry Institute of Sao Paulo University, Sao Paulo, Brazil
| | - Liu Wei
- Department of Dermatology, The General Hospital of Air Force PLA, Beijing, China
| | | | | | | | - Brigitte Dreno
- Nantes University, Univ Angers, INSERM, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302,0 Nantes, France
| | - Jean Krutmann
- IUF Leibniz Research Institute for Environmental Medicine, Duesseldorf, Germany
| |
Collapse
|
|
5
|
Li H, Robinson K, Lan L, Baughan N, Chan CW, Embury M, Whitman GJ, El-Zein R, Bedrosian I, Giger ML. Temporal Machine Learning Analysis of Prior Mammograms for Breast Cancer Risk Prediction. Cancers (Basel) 2023; 15:2141. [PMID: 37046802 PMCID: PMC10093086 DOI: 10.3390/cancers15072141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2023] [Revised: 03/24/2023] [Accepted: 03/29/2023] [Indexed: 04/09/2023] Open
Abstract
The identification of women at risk for sporadic breast cancer remains a clinical challenge. We hypothesize that the temporal analysis of annual screening mammograms, using a long short-term memory (LSTM) network, could accurately identify women at risk of future breast cancer. Women with an imaging abnormality, which had been biopsy-confirmed to be cancer or benign, who also had antecedent imaging available were included in this case-control study. Sequences of antecedent mammograms were retrospectively collected under HIPAA-approved guidelines. Radiomic and deep-learning-based features were extracted on regions of interest placed posterior to the nipple in antecedent images. These features were input to LSTM recurrent networks to classify whether the future lesion would be malignant or benign. Classification performance was assessed using all available antecedent time-points and using a single antecedent time-point in the task of lesion classification. Classifiers incorporating multiple time-points with LSTM, based either on deep-learning-extracted features or on radiomic features, tended to perform statistically better than chance, whereas those using only a single time-point failed to show improved performance compared to chance, as judged by area under the receiver operating characteristic curves (AUC: 0.63 ± 0.05, 0.65 ± 0.05, 0.52 ± 0.06 and 0.54 ± 0.06, respectively). Lastly, similar classification performance was observed when using features extracted from the affected versus the contralateral breast in predicting future unilateral malignancy (AUC: 0.63 ± 0.05 vs. 0.59 ± 0.06 for deep-learning-extracted features; 0.65 ± 0.05 vs. 0.62 ± 0.06 for radiomic features). The results of this study suggest that the incorporation of temporal information into radiomic analyses may improve the overall classification performance through LSTM, as demonstrated by the improved discrimination of future lesions as malignant or benign. Further, our data suggest that a potential field effect, changes in the breast extending beyond the lesion itself, is present in both the affected and contralateral breasts in antecedent imaging, and, thus, the evaluation of either breast might inform on the future risk of breast cancer.
Collapse
Affiliation(s)
- Hui Li
- Department of Radiology, The University of Chicago, Chicago, IL 60637, USA; (H.L.)
| | - Kayla Robinson
- Department of Radiology, The University of Chicago, Chicago, IL 60637, USA; (H.L.)
| | - Li Lan
- Department of Radiology, The University of Chicago, Chicago, IL 60637, USA; (H.L.)
| | - Natalie Baughan
- Department of Radiology, The University of Chicago, Chicago, IL 60637, USA; (H.L.)
| | - Chun-Wai Chan
- Department of Radiology, The University of Chicago, Chicago, IL 60637, USA; (H.L.)
| | - Matthew Embury
- Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Gary J. Whitman
- Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Randa El-Zein
- Department of Radiology, Houston Methodist Research Institute, Houston, TX 77030, USA
| | - Isabelle Bedrosian
- Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Maryellen L. Giger
- Department of Radiology, The University of Chicago, Chicago, IL 60637, USA; (H.L.)
| |
Collapse
|
|
6
|
Khani Jeihooni A, Moayedi ZS, Momenabadi V, Ghalegolab F, Afzali Harsini P. Effect of Educational Intervention Based on Theory of Planned Behavior (TPB) on Doing Breast Self-examination in a Sample of Iranian Women. Breast Cancer (Auckl) 2023; 17:11782234221145417. [PMID: 36727092 PMCID: PMC9884953 DOI: 10.1177/11782234221145417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2022] [Accepted: 09/02/2022] [Indexed: 01/27/2023] Open
Abstract
Background Breast self-examination (BSE) is an important part of health care for all women in every stage of life. This study aimed to investigate the effect of theory of planned behavior (TPB) on doing BSE in a sample of Iranian women. Methods A cross-sectional study was carried out to examine the factors affecting the BSE in 400 women. Then, a quasi-experimental study was conducted on 200 subjects (100 in experimental group and 100 in control group). The educational intervention for the experimental group consisted of 8 training sessions. A questionnaire including demographic characteristics, knowledge, and constructs of TPB was used to measure BSE performance before and 6 months after the intervention. Constructs of attitude, subjective norms, and perceived behavioral control predicted the intention to do the BSE. Results The mean age of the subjects was 31.65 ± 7.59 years. The studied variables predicted 38.7% of behavioral intention (P < .001, odds ratio = 0.387). Six months after the intervention, the experimental group showed a significant increase in the knowledge, attitude, perceived behavioral control, subjective norms, intention, and BSE performance compared with the control group (P < .001). Conclusions This study showed that educational intervention based on the TPB was effective in promoting breast cancer screening behavior such as BSE. Therefore, it is suggested that health educators and health care planners use educational texts based on these constructs of TPB to increase their influence on individuals via screening behavior for breast cancer.
Collapse
Affiliation(s)
- Ali Khani Jeihooni
- Nutrition Research Center, Department
of Public Health, School of Health, Shiraz University of Medical Sciences, Shiraz,
Iran,Ali Khani Jeihooni, Nutrition Research
Center, Department of Public Health, School of Health, Shiraz University of
Medical Sciences, P.O.Box: 71645-111, Shiraz, Iran.
| | - Zahra Sadat Moayedi
- Department of Public Health, Fasa
University of Medical Sciences, Fasa, Iran
| | - Victoria Momenabadi
- Department of Public Health, School of
Health, Bam University of Medical Sciences, Bam, Iran
| | - Farzaneh Ghalegolab
- Department of Public Health, School of
Health, Yasuj University of Medical Sciences, Yasuj, Iran
| | - Pooyan Afzali Harsini
- Department of Public Health, School of
Health, Kermanshah University of Medical Sciences, Kermanshah, Iran
| |
Collapse
|
|
7
|
Pang XL, Du HF, Nie F, Yang XG, Xu Y. Tubulin Alpha-1b as a Potential Biomarker for Lung Adenocarcinoma Diagnosis and Prognosis. Technol Cancer Res Treat 2023; 22:15330338231178391. [PMID: 37489256 PMCID: PMC10369087 DOI: 10.1177/15330338231178391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2023] [Revised: 04/25/2023] [Accepted: 05/09/2023] [Indexed: 07/26/2023] Open
Abstract
Background: Because lung cancer is the main cause of cancer deaths and lung adenocarcinoma (LUAD) accounts for more than 40% of all lung malignancies, it is essential to develop clinically useful biomarkers for the disease. The aim of this investigation is to assess the potential application of tubulin alpha-1b (TUBA1B) as a biomarker for diagnosing and monitoring the outcome of LUAD. Methods: The clinical data of the LUAD patients was retrospectively analyzed. Immunohistochemistry (IHC) analysis of a tissue microarray containing 90 LUAD cases was implemented to examine the expression of TUBA1B. The protein and mRNA levels of TUBA1B in serum were detected by enzyme-linked immunosorbent assay (ELISA) and quantitative real-time PCR (qRT-PCR) analysis respectively. UALCAN was employed to confirm the expression levels and survival probability of TUBA1B in LUAD patients. Results: Compared to adjacent non-cancerous tissues in the microarray, the expression of TUBA1B in LUAD tissues was much higher. The expression of TUBA1B in LUAD was statistically correlated with lymph node status (P = .031). Moreover, patients with higher TUBA1B expression had shorter overall survival (P < .0001). Furthermore, cox multi-factor analysis also suggested that TUBA1B may be an independent predictor for LUAD prognosis (P = .030). The results of TCGA data analysis by UALCAN were consistent with the microarray results, except for that TUBA1B was also significantly correlated with clinical tumor stages. Protein levels of TUBA1B in serum were obviously elevated in LUAD patients than control (P < .0001), and the area under the ROC curve was 0.99. TUBA1B also showed better sensitivity of 92.9% for LUAD than common clinical biomarkers. Conclusion: TUBA1B may be a non-invasive prognostic and diagnostic biomarker for LUAD patients.
Collapse
Affiliation(s)
- Xue-Li Pang
- School of Clinical Medicine, Chengdu Medical College, Chengdu, China
- Department of Clinical Laboratory, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China
| | - Hong-Fei Du
- School of Clinical Medicine, Chengdu Medical College, Chengdu, China
- Department of Clinical Laboratory, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China
| | - Fang Nie
- Department of Clinical Laboratory, Second People's Hospital of Chengdu, Chengdu, China
| | - Xiang-Gui Yang
- School of Clinical Medicine, Chengdu Medical College, Chengdu, China
- Department of Clinical Laboratory, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China
| | - Ying Xu
- School of Clinical Medicine, Chengdu Medical College, Chengdu, China
- Department of Clinical Laboratory, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China
| |
Collapse
|
|
8
|
Elmorsy MR, Eltoukhi M, Fadda AA, Abdel-Latif E, Abdelmoaz MA. Synthesis of New Carbazole–Thiazole Analogues and Evaluating their Anticancer Activity. Polycycl Aromat Compd 2022. [DOI: 10.1080/10406638.2022.2144909] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Mohamed R. Elmorsy
- Department of Chemistry, Faculty of Science, Mansoura University, Mansoura, Egypt
| | - Mariam Eltoukhi
- Department of Chemistry, Faculty of Science, Mansoura University, Mansoura, Egypt
| | - Ahmed A. Fadda
- Department of Chemistry, Faculty of Science, Mansoura University, Mansoura, Egypt
| | - Ehab Abdel-Latif
- Department of Chemistry, Faculty of Science, Mansoura University, Mansoura, Egypt
| | - Miral A. Abdelmoaz
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Sinai University, Kantra, Egypt
| |
Collapse
|
|
9
|
Forrai G, Kovács E, Ambrózay É, Barta M, Borbély K, Lengyel Z, Ormándi K, Péntek Z, Tünde T, Sebő É. Use of Diagnostic Imaging Modalities in Modern Screening, Diagnostics and Management of Breast Tumours 1st Central-Eastern European Professional Consensus Statement on Breast Cancer. Pathol Oncol Res 2022; 28:1610382. [PMID: 35755417 PMCID: PMC9214693 DOI: 10.3389/pore.2022.1610382] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/20/2022] [Accepted: 04/29/2022] [Indexed: 12/11/2022]
Abstract
Breast radiologists and nuclear medicine specialists updated their previous recommendation/guidance at the 4th Hungarian Breast Cancer Consensus Conference in Kecskemét. A recommendation is hereby made that breast tumours should be screened, diagnosed and treated according to these guidelines. These professional guidelines include the latest technical developments and research findings, including the role of imaging methods in therapy and follow-up. It includes details on domestic development proposals and also addresses related areas (forensic medicine, media, regulations, reimbursement). The entire material has been agreed with the related medical disciplines.
Collapse
Affiliation(s)
- Gábor Forrai
- GÉ-RAD Kft., Budapest, Hungary
- Duna Medical Center, Budapest, Hungary
| | - Eszter Kovács
- GÉ-RAD Kft., Budapest, Hungary
- Duna Medical Center, Budapest, Hungary
| | | | | | - Katalin Borbély
- National Institute of Oncology, Budapest, Hungary
- Ministry of Human Capacities, Budapest, Hungary
| | | | | | | | - Tasnádi Tünde
- Dr Réthy Pál Member Hospital of Békés County Central Hospital, Békéscsaba, Hungary
| | - Éva Sebő
- Kenézy Gyula University Hospital, University of Debrecen, Debrecen, Hungary
| |
Collapse
|
|
10
|
Zhou Q, Ju LL, Ji X, Cao YL, Shao JG, Chen L. Plasma circRNAs as Biomarkers in Cancer. Cancer Manag Res 2021; 13:7325-7337. [PMID: 34584458 PMCID: PMC8464305 DOI: 10.2147/cmar.s330228] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Accepted: 08/26/2021] [Indexed: 12/20/2022] Open
Abstract
The incidence and mortality of cancer are increasing each year. At present, the sensitivity and specificity of the blood biomarkers that were used in clinical practice are low, which make the detection rate of cancer decrease. With advances in bioinformatics and technology, some non-coding RNA as biomarkers can be easily detected through some traditional and new technologies. Circular RNAs (circRNAs) are non-coding RNAs, that is, they do not encode proteins, and have important regulatory functions. CircRNAs can remain stable in bodily fluids, such as in saliva, blood, urine, and especially plasma. The difference in the expression of plasma circRNAs between cancer patients and normal people may suggest that plasma circRNAs may play an important role in the occurrence and development of cancer. In this review, we summarized the clinical effect of plasma circRNAs in several high-incidence cancers. CircRNAs may be effective biomarkers for tumour diagnosis, treatment selection and prognosis evaluation.
Collapse
Affiliation(s)
- Qian Zhou
- Medical School of Nantong University, Nantong Third People's Hospital, Nantong, Jiangsu, People's Republic of China
| | - Lin-Ling Ju
- Nantong Institute of Liver Disease, Nantong Third People's Hospital, Nantong University, Nantong, Jiangsu, People's Republic of China
| | - Xiang Ji
- Medical School of Nantong University, Nantong Third People's Hospital, Nantong, Jiangsu, People's Republic of China
| | - Ya-Li Cao
- Nantong Institute of Liver Disease, Nantong Third People's Hospital, Nantong University, Nantong, Jiangsu, People's Republic of China
| | - Jian-Guo Shao
- Nantong Institute of Liver Disease, Nantong Third People's Hospital, Nantong University, Nantong, Jiangsu, People's Republic of China
| | - Lin Chen
- Nantong Institute of Liver Disease, Nantong Third People's Hospital, Nantong University, Nantong, Jiangsu, People's Republic of China
| |
Collapse
|
|
11
|
Flitcroft JG, Verheyen J, Vemulkar T, Welbourne EN, Rossi SH, Welsh SJ, Cowburn RP, Stewart GD. Early detection of kidney cancer using urinary proteins: a truly non-invasive strategy. BJU Int 2021; 129:290-303. [PMID: 34570419 DOI: 10.1111/bju.15601] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
OBJECTIVES To review urinary protein biomarkers as potential non-invasive, easily obtainable, early diagnostic tools in renal cell carcinoma (RCC). METHODS A PubMed database search was performed up to the year 2020 to identify primary studies reporting potential urinary protein biomarkers for RCC. Separate searches were conducted to identify studies describing appropriate methods of developing cancer screening programmes and detection of cancer biomarkers. RESULTS Several urinary protein biomarkers are under validation for RCC diagnostics, e.g. aquaporin-1, perilipin-2, carbonic anhydrase-9, Raf-kinase inhibitory protein, nuclear matrix protein-22, 14-3-3 Protein β/α and neutrophil gelatinase-associated lipocalin. However, none has yet been validated or approved for clinical use due to low sensitivity or specificity, inconsistencies in appropriate study design, or lack of external validation. CONCLUSIONS Evaluation of biomarkers' feasibility, sample preparation and storage, biomarker validation, and the application of novel technologies may provide a solution that maximises the potential for a truly non-invasive biomarker in early RCC diagnostics.
Collapse
Affiliation(s)
- Jordan G Flitcroft
- Cavendish Laboratory, Department of Physics, University of Cambridge, Cambridge, UK
| | - Jeroen Verheyen
- Department of Surgery, Addenbrookes Hospital, University of Cambridge, Cambridge, UK
| | - Tarun Vemulkar
- Cavendish Laboratory, Department of Physics, University of Cambridge, Cambridge, UK
| | - Emma N Welbourne
- Cavendish Laboratory, Department of Physics, University of Cambridge, Cambridge, UK
| | - Sabrina H Rossi
- Department of Surgery, Addenbrookes Hospital, University of Cambridge, Cambridge, UK
| | - Sarah J Welsh
- Department of Surgery, Addenbrookes Hospital, University of Cambridge, Cambridge, UK
| | - Russell P Cowburn
- Cavendish Laboratory, Department of Physics, University of Cambridge, Cambridge, UK
| | - Grant D Stewart
- Department of Surgery, Addenbrookes Hospital, University of Cambridge, Cambridge, UK
| |
Collapse
|
|
12
|
Exploring the synthesis and characterization of fac-Re(CO)3L complexes using diethylenetriamine derivative functionalized at the central nitrogen. Inorganica Chim Acta 2021. [DOI: 10.1016/j.ica.2021.120291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
|
13
|
Choi HG, Bang WJ, Jo JK, Oh CY, Shim M, Cho JS. The association between family history of prostate cancer and development of prostate cancer among Korean population: A prospective cohort study using KoGES data. Medicine (Baltimore) 2021; 100:e24757. [PMID: 33607822 PMCID: PMC7899810 DOI: 10.1097/md.0000000000024757] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Accepted: 01/25/2021] [Indexed: 01/05/2023] Open
Abstract
This study aimed to assess the impact of family history (FH) on prostate cancer (PCa) development among a general Korean population. We conducted a prospective cohort study based on the registry records of 211,789 participants in the database of the Korean Genome and Epidemiology Study from 2001 to 2013. A total of 69,693 men with appropriate records were evaluated by being categorizing into 2 groups; a PCa group (100) and control group (69,593). FH of PCa was also categorized as FH of total, father, or brother. Odds ratios (ORs) of PCa development were calculated by using stratified logistic regression models. The adjusted OR of PCa history of father was 27.7 (95% confidence interval [CI] = 9.7-79.2, P < .001) in PCa patients compared to control, and that of PCa history of brother was 15.8 (95% CI = 3.6-69.6, P < .001). Among the adjusted variables, age (OR, 1.17; 95% CI, 1.14-1.21; P < .001), and hyperlipidemia (OR, 2.25; CI, 1.32-3.84; P = .003) were also identified as significant predictors of PCa development. There was no difference in the impact of FH on PCa development between different age groups at PCa diagnosis (<60 vs ≥60 years). To our knowledge, this study represents the first prospective cohort study based on the registry data of a Korean population showing the significance of FH on PCa development. Additionally, the effect of FH on the early onset of PCa has not been confirmed in our analysis.
Collapse
Affiliation(s)
- Hyo Geun Choi
- Department of Otorhinolaryngology-Head & Neck Surgery
- Hallym Data Science Laboratory
| | - Woo Jin Bang
- Department of Urology, Hallym University College of Medicine, Anyang
| | - Jung Ki Jo
- Department of Urology, Hanyang University College of Medicine, Seoul, Korea
| | - Cheol Young Oh
- Department of Urology, Hallym University College of Medicine, Anyang
| | - Myungsun Shim
- Department of Urology, Hallym University College of Medicine, Anyang
| | - Jin Seon Cho
- Department of Urology, Hallym University College of Medicine, Anyang
| |
Collapse
|
|
14
|
Bartzatt R. Prostate Cancer: Biology, Incidence, Detection Methods, Treatment Methods, and Vaccines. Curr Top Med Chem 2021; 20:847-854. [PMID: 32091336 DOI: 10.2174/1568026620666200224100730] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2019] [Revised: 12/18/2019] [Accepted: 12/24/2019] [Indexed: 12/14/2022]
Abstract
Cancer of the prostate are cancers in which most incidences are slow-growing, and in the U.S., a record of 1.2 million new cases of prostate cancer occurred in 2018. The rates of this type of cancer have been increasing in developing nations. The risk factors for prostate cancer include age, family history, and obesity. It is believed that the rate of prostate cancer is correlated with the Western diet. Various advances in methods of radiotherapy have contributed to lowering morbidity. Therapy for hormone- refractory prostate cancer is making progress, for almost all men with metastases will proceed to hormone-refractory prostate cancer. Smoking cigarettes along with the presence of prostate cancer has been shown to cause a higher risk of mortality in prostate cancer. The serious outcome of incontinence and erectile dysfunction result from the cancer treatment of surgery and radiation, particularly for prostate- specific antigen detected cancers that will not cause morbidity or mortality. Families of patients, as well as patients, are profoundly affected following the diagnosis of prostate cancer. Poor communication between spouses during prostate cancer increases the risk for poor adjustment to prostate cancer. The use of serum prostate-specific antigen to screen for prostate cancer has led to a greater detection, in its early stage, of this cancer. Prostate cancer is the most common malignancy in American men, accounting for more than 29% of all diagnosed cancers and about 13% of all cancer deaths. A shortened course of hormonal therapy with docetaxel following radical prostatectomy (or radiation therapy) for high-risk prostate cancer has been shown to be both safe and feasible. Patients treated with docetaxel-estramustine had a prostate-specific antigen response decline of at least 50%. Cancer vaccines are an immune-based cancer treatment that may provide the promise of a non-toxic but efficacious therapeutic alternative for cancer patients. Further studies will elucidate improved methods of detection and treatment.
Collapse
Affiliation(s)
- Ronald Bartzatt
- Durham Science Center, College of Arts and Sciences, University of Nebraska at Omaha, 6001 Dodge Street, Omaha, Nebraska 68182, United States
| |
Collapse
|
|
15
|
Ali T, Masood K, Irfan M, Draz U, Nagra AA, Asif M, Alshehri BM, Glowacz A, Tadeusiewicz R, Mahnashi MH, Yasin S. Multistage Segmentation of Prostate Cancer Tissues Using Sample Entropy Texture Analysis. ENTROPY 2020; 22:e22121370. [PMID: 33279915 PMCID: PMC7761953 DOI: 10.3390/e22121370] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/10/2020] [Revised: 11/24/2020] [Accepted: 12/01/2020] [Indexed: 12/12/2022]
Abstract
In this study, a multistage segmentation technique is proposed that identifies cancerous cells in prostate tissue samples. The benign areas of the tissue are distinguished from the cancerous regions using the texture of glands. The texture is modeled based on wavelet packet features along with sample entropy values. In a multistage segmentation process, the mean-shift algorithm is applied on the pre-processed images to perform a coarse segmentation of the tissue. Wavelet packets are employed in the second stage to obtain fine details of the structured shape of glands. Finally, the texture of the gland is modeled by the sample entropy values, which identifies epithelial regions from stroma patches. Although there are three stages of the proposed algorithm, the computation is fast as wavelet packet features and sample entropy values perform robust modeling for the required regions of interest. A comparative analysis with other state-of-the-art texture segmentation techniques is presented and dice ratios are computed for the comparison. It has been observed that our algorithm not only outperforms other techniques, but, by introducing sample entropy features, identification of cancerous regions of tissues is achieved with 90% classification accuracy, which shows the robustness of the proposed algorithm.
Collapse
Affiliation(s)
- Tariq Ali
- Department of Computer Science, Sahiwal Campus, COMSATS University Islamabad, Sahiwal 57000, Pakistan;
| | - Khalid Masood
- Department of Computer Science, Lahore Garrison University, Lahore 54792, Pakistan; (K.M.); (A.A.N.); (M.A.)
| | - Muhammad Irfan
- Electrical Engineering Department, College of Engineering, Najran University, Najran 61441, Saudi Arabia
- Correspondence: (M.I.); (U.D.); (A.G.)
| | - Umar Draz
- Department of Computer Science, University of Sahiwal, Sahiwal, Punjab 57000, Pakistan
- Correspondence: (M.I.); (U.D.); (A.G.)
| | - Arfan Ali Nagra
- Department of Computer Science, Lahore Garrison University, Lahore 54792, Pakistan; (K.M.); (A.A.N.); (M.A.)
| | - Muhammad Asif
- Department of Computer Science, Lahore Garrison University, Lahore 54792, Pakistan; (K.M.); (A.A.N.); (M.A.)
| | - Bandar M. Alshehri
- Department of Clinical Laboratory, Faculty of Applied Medical Sciences, Najran University, P.O. Box 1988, Najran 61441, Saudi Arabia;
| | - Adam Glowacz
- Department of Automatic Control and Robotics, Faculty of Electrical Engineering, Automatics, Computer Science and Biomedical Engineering, AGH University of Science and Technology, al. A. Mickiewicza 30, 30-059 Kraków, Poland
- Correspondence: (M.I.); (U.D.); (A.G.)
| | - Ryszard Tadeusiewicz
- Department of Biocybernetics and Biomedical Engineering, Faculty of Electrical Engineering, Automatics, Computer Science and Biomedical Engineering, AGH University of Science and Technology, al. A. Mickiewicza 30, 30-059 Kraków, Poland;
| | - Mater H. Mahnashi
- Department of Medicinal Chemistry, Pharmacy School, Najran University, Najran 61441, Saudi Arabia;
| | - Sana Yasin
- Department of Computer Science, University of Okara, Okara 56130, Pakistan;
| |
Collapse
|
|
16
|
BRDT promotes ovarian cancer cell growth. Cell Death Dis 2020; 11:1021. [PMID: 33257688 PMCID: PMC7705741 DOI: 10.1038/s41419-020-03225-y] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2020] [Revised: 10/29/2020] [Accepted: 10/30/2020] [Indexed: 12/18/2022]
Abstract
Bromodomain testis-specific factor (BRDT) is a member of the bromodomain and extra-terminal (BET) family proteins. Its expression and potential functions in ovarian cancer were examined. We show that BRDT is overexpressed in human ovarian cancer tissues and in established (CaOV3)/primary ovarian cancer cells. However, its expression is low in ovarian epithelial tissues and cells. Significantly, shRNA-induced silencing or CRISPR/Cas9-mediated knockout of BRDT inhibited ovarian cancer cell growth, viability, proliferation and migration, and induced significant apoptosis activation. Conversely, exogenous overexpression of BRDT, by a lentiviral construct, augmented CaOV3 cell proliferation and migration. In CaOV3 cells expression of two key BRDT target genes, polo-like kinase 1 (PLK1) and aurora kinase C (AURKC), was downregulated by BRDT shRNA or knockout, but upregulated with BRDT overexpression. In vivo, xenograft tumors-derived from BRDT-knockout CaOV3 cells grew significantly slower than control tumors in severe combined immunodeficient (SCID) mice. Furthermore, intratumoral injection of BRDT shRNA lentivirus potently inhibited the growth of primary ovarian cancer xenografts in SCID mice. Downregulation of PLK1 and AURKC was detected in BRDT-knockout and BRDT-silenced tumor tissues. Collectively, BRDT overexpression promotes ovarian cancer cell progression. Targeting BRDT could be a novel strategy to treat ovarian cancer.
Collapse
|
|
17
|
Lu GJ, Cui J, Qian Q, Hou ZB, Xie HY, Hu W, Hao KK, Xia N, Zhang Y. Overexpression of hsa_circ_0001715 is a Potential Diagnostic and Prognostic Biomarker in Lung Adenocarcinoma. Onco Targets Ther 2020; 13:10775-10783. [PMID: 33122916 PMCID: PMC7591015 DOI: 10.2147/ott.s274932] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2020] [Accepted: 09/25/2020] [Indexed: 01/16/2023] Open
Abstract
Background Circular RNAs (circRNAs) play important roles in tumorigenesis, including lung cancer. However, the expression profile and clinical value of circRNAs in lung adenocarcinoma remain unclear. The purpose of this study was to establish the circRNAs expression profile of lung adenocarcinoma and determine its potential diagnostic and prognostic value. Materials and Methods The global expression profile of circRNAs in lung adenocarcinoma tissue was determined from five paired lung adenocarcinoma tissues and adjacent normal tissues. The expression levels of selected candidate circRNA were validated by qRT-PCR. Sequence analysis was used to confirm the specificity of amplified circRNA. The candidate circRNA level was further detected in plasma samples from lung adenocarcinoma patients and healthy controls. The relationships between their levels and clinicopathological factors were explored. Receiver operating characteristic (ROC) curve was constructed to differentiate lung adenocarcinoma from healthy controls. Kaplan–Meier was performed to show survival curves and survival characteristics. The significance of different prognostic factors for overall survival (OS) was analyzed using Cox proportional hazards model. Results CircRNA microarray showed 394 circRNAs were differentially expressed, including 215 up-regulated and 179 down-regulated circRNAs. Hsa_circ_0001715 was the most up-regulated circRNA in lung adenocarcinoma tissues. Plasma hsa_circ_0001715 levels were significantly higher in lung adenocarcinoma patients versus healthy controls (P < 0.001). We further found that high plasma hsa_circ_0001715 was significantly correlated with TNM stage (P = 0.039) and distant metastasis (P = 0.030). Furthermore, ROC curve analysis showed that hsa_circ_0001715 had high diagnostic value, and the area under the curve (AUC) was 0.871. Lung adenocarcinoma patients with plasma hsa_circ_0001715 levels over 0.417 had significantly shorter OS than those with lower levels (P = 0.004). Univariate and multivariate survival analysis showed that plasma hsa_circ_0001715 level was an independent prognostic factor for the OS. Conclusion Our study revealed an aberrant circRNA expression profile in lung adenocarcinoma, and hsa_circ_0001715 is up-regulated and could act as a novel diagnostic and prognostic biomarker for lung adenocarcinoma.
Collapse
Affiliation(s)
- Guo-Jun Lu
- Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing, Jiangsu 210029, People's Republic of China.,Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu 210029, People's Republic of China
| | - Jian Cui
- Department of Radiology, Zhongda Hospital, Medical School of Southeast University, Nanjing, Jiangsu 210009, People's Republic of China
| | - Qian Qian
- Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing, Jiangsu 210029, People's Republic of China.,Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu 210029, People's Republic of China
| | - Zhi-Bo Hou
- Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing, Jiangsu 210029, People's Republic of China.,Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu 210029, People's Republic of China
| | - Hai-Yan Xie
- Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing, Jiangsu 210029, People's Republic of China.,Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu 210029, People's Republic of China
| | - Wei Hu
- Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing, Jiangsu 210029, People's Republic of China.,Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu 210029, People's Republic of China
| | - Ke-Ke Hao
- Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing, Jiangsu 210029, People's Republic of China.,Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu 210029, People's Republic of China
| | - Ning Xia
- Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing, Jiangsu 210029, People's Republic of China.,Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu 210029, People's Republic of China
| | - Yu Zhang
- Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing, Jiangsu 210029, People's Republic of China.,Nanjing Brain Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu 210029, People's Republic of China
| |
Collapse
|
|
18
|
Zhang X, Wang Y, Zhao A, Kong F, Jiang L, Wang J. Long Non-Coding RNA LINC00511 Accelerates Proliferation and Invasion in Cervical Cancer Through Targeting miR-324-5p/DRAM1 Axis. Onco Targets Ther 2020; 13:10245-10256. [PMID: 33116605 PMCID: PMC7567551 DOI: 10.2147/ott.s255067] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2020] [Accepted: 08/29/2020] [Indexed: 12/16/2022] Open
Abstract
Purpose Cervical cancer is the second most prevalent female malignance, and human papillomavirus (HPV) infection is the main pathogenic factor of cervical cancer. Emerging evidence has revealed that a number of long non-coding RNAs (lncRNAs) play critical roles in the tumorigenesis and progression of cervical cancer. The aim of this study was to further investigate the precise role of lncRNA LINC00511 in HPV-negative and HPV-positive cervical cancer cells and explore the potential regulatory mechanism. Methods The expression of LINC00511 in cervical cancer and cell lines was examined by RT-PCR. Fluorescence in situ hybridization analysis (FISH) assay was performed to detect the localization of LINC00511 in cervical cancer cells. Loss-of-function experiments of LINC00511 by siRNA interference were performed to assess its effects on HPV-negative and HPV-positive cervical cancer cells. Dual-luciferase reporter and RNA immunoprecipitation (RIP) assays were used to identify the target of LINC00511. Relative expression of related proteins was detected using Western blot. Results Herein, the results showed that LINC00511 was significantly up-regulated in cervical cancer and cell lines and mainly distributed in the cytoplasm of cervical cancer cells. Loss-of-function experiments indicated that silencing of LINC00511 inhibited the proliferation and invasion of both HPV-negative and HPV-positive cervical cancer cells, as well as promoted apoptosis by regulating the Bcl-2/Bax axis and Caspase 3 activation. Bioinformatic analysis, dual-luciferase reporter, and RIP assays showed that LINC00511 was a target of miR-324-5p, while DRAM1 was a direct target of miR-324-5p. The expression of miR-324-5p was down-regulated in cervical cancer, while the expression of DRAM1 was up-regulated. Moreover, the expression of LINC00511 was negatively correlated with miR-324-5p expression in cervical cancer tissues and positively correlated with DRAM1. Further, DRAM1 overexpression promoted both HPV-negative and HPV-positive cervical cancer cell proliferation and invasion, which could be reversed by miR-324-5p mimics or si-LINC00511. Conclusion Collectively, these results suggest that LINC00511 functions as a competing endogenous RNA (ceRNA) to regulate the miR-324-5p/DRAM1 axis, leading to HPV-negative and HPV-positive cervical cancer aggravation.
Collapse
Affiliation(s)
- Xin Zhang
- Department of Oncology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, People's Republic of China
| | - Yuyan Wang
- Department of Obstetrics and Gynecology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, People's Republic of China
| | - Anqi Zhao
- Capital Medical University, Beijing 100069, People's Republic of China
| | - Fanshuang Kong
- Department of General Surgery, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, People's Republic of China
| | - Lipeng Jiang
- Department of Obstetrics and Gynecology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, People's Republic of China
| | - Jinfeng Wang
- Department of Pediatrics, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, People's Republic of China
| |
Collapse
|
|
19
|
Antabe R, Kansanga M, Sano Y, Kyeremeh E, Galaa Y. Utilization of breast cancer screening in Kenya: what are the determinants? BMC Health Serv Res 2020; 20:228. [PMID: 32183801 PMCID: PMC7079358 DOI: 10.1186/s12913-020-5073-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2019] [Accepted: 03/04/2020] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Breast cancer accounts for 23% of all cancer cases among women in Kenya. Although breast cancer screening is important, we know little about the factors associated with women's breast cancer screening utilization in Kenya. Using the Andersen's behavioural model of health care utilization, we aim to address this void in the literature. METHODS We draw data on the Kenya Demographic and Health Survey and employ univariate, bivariate, and multivariate analyses. RESULTS We find that women's geographic location, specifically, living in a rural area (OR = 0.89; p < 0.001) and the North Eastern Province is associated with lower odds of women being screened for breast cancer. Moreover, compared to the more educated, richer and insured, women who are less educated, poorer, and uninsured (OR = 0.74; p < 0.001) are less likely to have been screened for breast cancer. CONCLUSION Based on these findings, we recommend place and group-specific education and interventions on increasing breast cancer screening in Kenya.
Collapse
Affiliation(s)
- Roger Antabe
- Department of Geography, Western University, 1151 Richmond Street, Social Science Building, London, Ontario, N6A 3K7, Canada
| | - Moses Kansanga
- Department of Geography, Western University, 1151 Richmond Street, Social Science Building, London, Ontario, N6A 3K7, Canada
| | - Yujiro Sano
- Department of Sociology, Western University, 1151 Richmond Street, Social Science Building, London, Ontario, N6A 3K7, Canada
| | - Emmanuel Kyeremeh
- Department of Geography, Western University, 1151 Richmond Street, Social Science Building, London, Ontario, N6A 3K7, Canada
| | - Yvonne Galaa
- Department of Planning, Kwame Nkrumah University of Science and Technology, Private Mail Bag, University Post Office, KNUST, Kumasi, Ghana.
| |
Collapse
|
|
20
|
Takeuchi E, Kim Y, Shaffer KM, Cannady RS, Carver CS. Fear of cancer recurrence promotes cancer screening behaviors among family caregivers of cancer survivors. Cancer 2020; 126:1784-1792. [PMID: 31913499 DOI: 10.1002/cncr.32701] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2019] [Revised: 11/25/2019] [Accepted: 11/25/2019] [Indexed: 11/10/2022]
Abstract
BACKGROUND Fear of cancer recurrence (FCR) has been associated with cancer screening behaviors among cancer survivors, but to the authors' knowledge, the question of whether the same is true for caregivers is unknown. The current study investigated the extent to which FCR among caregivers predicted their cancer screening behaviors years after their relatives' cancer diagnosis. METHODS A total of 813 caregivers (67% of whom were female, mean age of 56 years, and 92% non-Hispanic white) completed surveys 2 years (T1) and 8 years (T2) after their patients' cancer diagnosis. FCR, anxiety (Profile of Mood States-Short Form [POMS-SF]), and general mental health (Medical Outcomes Study 36-Item Short-Form Health Survey [MOS SF-36]) were reported at T1; caregivers' engagement in screening for colorectal, breast, and prostate cancers because of the patients' diagnoses were reported at T2. RESULTS Caregivers were found to engage in cancer screening at rates similar to those of the national average. Controlling for covariates, hierarchical logistic regression modeling for each type of cancer screening demonstrated that greater FCR was linearly related to a higher likelihood of undergoing colorectal cancer screening (odds ratio [OR], 1.15) and maintaining prostate cancer screening (OR, 1.34), but a lower likelihood of maintaining breast cancer screening in an age-appropriate manner (OR, 0.27). Examining curvilinear effects demonstrated that moderate levels of FCR were associated with a higher likelihood of maintaining age-appropriate colorectal cancer screening (OR, 1.48). CONCLUSIONS The overall FCR among caregivers uniquely promotes their engagement in cancer screening behaviors. The role of caregivers' FCR in other types of cancer preventive behaviors and ways to channel FCR concerns into promoting healthy lifestyle behaviors should be investigated.
Collapse
Affiliation(s)
- Emi Takeuchi
- Department of Psychology, University of Miami, Coral Gables, Florida.,Graduate School of Medicine, Keio University, Tokyo, Japan.,Center for Cancer Control and Information Service, National Cancer Center Japan, Tokyo, Japan.,Japan Society for the Promotion of Science, Tokyo, Japan
| | - Youngmee Kim
- Department of Psychology, University of Miami, Coral Gables, Florida
| | - Kelly M Shaffer
- Center for Behavioral Health and Technology, University of Virginia School of Medicine, Charlottesville, Virginia
| | - Rachel S Cannady
- Cancer Caregiver Support, American Cancer Society, Atlanta, Georgia
| | - Charles S Carver
- Department of Psychology, University of Miami, Coral Gables, Florida
| |
Collapse
|
|
21
|
Hassan ME, Mahran E. Effect of adding magnesium sulphate to bupivacaine on the clinical profile of ultrasound-guided thoracic paravertebral block in patients undergoing modified radical mastectomy. EGYPTIAN JOURNAL OF ANAESTHESIA 2019. [DOI: 10.1016/j.egja.2014.11.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Affiliation(s)
| | - Essam Mahran
- Department of Anaesthesia, ICU , National Cancer Institute , Cairo University , Egypt
| |
Collapse
|
|
22
|
Mousavi SM, Zarei M, Hashemi SA, Babapoor A, Amani AM. A conceptual review of rhodanine: current applications of antiviral drugs, anticancer and antimicrobial activities. ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY 2019; 47:1132-1148. [DOI: 10.1080/21691401.2019.1573824] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Affiliation(s)
- Seyyed Mojtaba Mousavi
- Department of Medical Nanotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran
- Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Maryam Zarei
- Department of Medical Nanotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran
- Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Seyyed Alireza Hashemi
- Department of Medical Nanotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran
- Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Aziz Babapoor
- Department of Chemical Engineering, University of Mohaghegh Ardabili, Ardabil, Iran
| | - Ali Mohammad Amani
- Department of Medical Nanotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran
- Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
| |
Collapse
|
|
23
|
Malhone C, Longatto-Filho A. Cervical, Ovarian and Endometrial Tumor Markers: Potential Clinical Value. Semin Ultrasound CT MR 2019; 40:350-357. [PMID: 31375174 DOI: 10.1053/j.sult.2019.03.003] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Tumors markers can be described as molecular products expressed by neoplasia tissues (immunohistochemistry), or metabolized and secreted by tumor and characterized biochemically in body fluids such as blood and urine. They may have utility as indicators of tumor stage and grade as well useful for monitoring responses to treatment and predicting recurrence, progression, development of metastases, or even patient survival. Unfortunately, in some cases they may have no identified clinical potential. Several investigations have been carried out, especially in the last decade, using biotechnological methods, in order to identify new potential tumor markers. By translating these findings into clinical use one may facilitate accurate diagnosis and prognostic prediction, and contribute to individualized treatment. The objective of this review is to describe some biomarkers with potential use in clinical settings of uterine cervix, ovary, and endometrium carcinomas.
Collapse
Affiliation(s)
- Carolina Malhone
- Sociedade Brasileira de Mastologia (Brazilian Society of Mastology), São Paulo, SP, Brazil
| | - Adhemar Longatto-Filho
- Department of Pathology, Laboratory of Medical Investigation (LIM), University of São Paulo School of Medicine, Sao Paulo, SP, Brazil; Life and Health Sciences Research Institute (ICVS), School of Medicine Nces, University of Minho, Braga, Portugal; ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal; Molecular Oncology Research Center, Barretos Cancer Hospital, Pio XII Foundation, Barretos, Brazil.
| |
Collapse
|
|
24
|
Konerman MA, Verma A, Zhao B, Singal AG, Lok AS, Parikh ND. Frequency and Outcomes of Abnormal Imaging in Patients With Cirrhosis Enrolled in a Hepatocellular Carcinoma Surveillance Program. Liver Transpl 2019; 25:369-379. [PMID: 30582779 PMCID: PMC6395491 DOI: 10.1002/lt.25398] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/19/2018] [Accepted: 12/13/2018] [Indexed: 12/31/2022]
Abstract
There are limited data on the downstream effects of hepatocellular carcinoma (HCC) surveillance, including the frequency of false-positive results. We aimed to quantify the incidence of indeterminate nodules (INs) and the follow-up testing needed to resolve these findings among patients enrolled in a structured HCC surveillance program. We retrospectively analyzed adult patients with cirrhosis enrolled in a structured HCC surveillance program in a large tertiary care center. Outcomes included surveillance benefits, defined as early HCC detection, and harm, defined as INs prompting additional diagnostic evaluation. Among 999 patients followed for a median of 2.2 years, HCC surveillance imaging was consistently completed every 6, 9, and 12 months in 46%, 51%, and 68% of patients, respectively. Of 256 (25.6%) patients with abnormal imaging, 69 (27.0%) were diagnosed with HCC and 187 (73.0%) with INs. Most HCC (n = 54, 78.3%) were found within Milan criteria. Among those with an IN, 78.1% returned to ultrasound surveillance after a median of 2 (interquartile range [IQR], 1-3) negative computed tomography (CT)/magnetic resonance imaging (MRI) scans, and 21.9% continued CT/MRI imaging (median, 1; IQR, 1-2). Eleven patients underwent diagnostic liver biopsy. Hypoalbuminemia, thrombocytopenia, and larger nodule size were independently associated with HCC diagnosis. In conclusion, 1 in 4 patients enrolled in an HCC surveillance program had abnormal surveillance imaging, but three-fourths of the lesions were INs, resulting in downstream harm. Improved risk-stratification tools are needed to identify nodules that are benign to reduce follow-up diagnostic evaluation.
Collapse
Affiliation(s)
- Monica A Konerman
- Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA
| | - Aashesh Verma
- Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA
| | - Betty Zhao
- Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA
| | - Amit G. Singal
- Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX
| | - Anna S Lok
- Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA
| | - Neehar D Parikh
- Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA
| |
Collapse
|
|
25
|
Abstract
Endometrial cancer is the most common gynecological malignancy in high-income countries. Although the overall prognosis is relatively good, high-grade endometrial cancers have a tendency to recur. Recurrence needs to be prevented since the prognosis for recurrent endometrial cancer is dismal. Treatment tailored to tumor biology is the optimal strategy to balance treatment efficacy against toxicity. Standard treatment consists of hysterectomy and bilateral salpingo-oophorectomy. Lymphadenectomy (with ongoing studies of sentinel node biopsy) enables identification of lymph node positive patients who need adjuvant treatment, including radiotherapy and chemotherapy. Adjuvant radiotherapy is used for Stage I-II patients with high-risk factors and Stage III lymph node negative patients. In advanced disease, a combination of surgery to no residual disease and chemotherapy results in the best outcome. Surgery for recurrent disease is only advocated in patients with a good performance status with a relatively long disease-free interval.
Collapse
Affiliation(s)
- Frédéric Amant
- Division of Gynecologic Oncology, University Hospitals Gasthuisberg, Leuven, Belgium.,Center for Gynecologic Oncology Amsterdam, Netherlands Cancer Institute, Amsterdam, Netherlands.,Center for Gynecologic Oncology Amsterdam, Amsterdam University Medical Centers, Amsterdam, Netherlands
| | - Mansoor Raza Mirza
- Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - Martin Koskas
- Division of Gynecologic Oncology, Bichat University Hospital, Paris, France
| | - Carien L Creutzberg
- Department of Radiation Oncology, Leiden University Medical Center, Leiden, Netherlands
| |
Collapse
|
|
26
|
Six-year prospective evaluation of second-look US with volume navigation for MRI-detected additional breast lesions. Eur Radiol 2018; 29:1799-1808. [DOI: 10.1007/s00330-018-5765-8] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2018] [Revised: 08/06/2018] [Accepted: 09/14/2018] [Indexed: 10/28/2022]
|
|
27
|
Giana FE, Bonetto FJ, Bellotti MI. Assay based on electrical impedance spectroscopy to discriminate between normal and cancerous mammalian cells. Phys Rev E 2018; 97:032410. [PMID: 29776129 DOI: 10.1103/physreve.97.032410] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2017] [Indexed: 11/07/2022]
Abstract
In this work we present an assay to discriminate between normal and cancerous cells. The method is based on the measurement of electrical impedance spectra of in vitro cell cultures. We developed a protocol consisting on four consecutive measurement phases, each of them designed to obtain different information about the cell cultures. Through the analysis of the measured data, 26 characteristic features were obtained for both cell types. From the complete set of features, we selected the most relevant in terms of their discriminant capacity by means of conventional statistical tests. A linear discriminant analysis was then carried out on the selected features, allowing the classification of the samples in normal or cancerous with 4.5% of false positives and no false negatives.
Collapse
Affiliation(s)
- Fabián Eduardo Giana
- Laboratorio de Cavitación y Biotecnología, Centro Atómico Bariloche, Río Negro, R8402AGP, Argentina.,Instituto Balseiro, Universidad Nacional de Cuyo/Comisión Nacional de Energía Atómica, Bariloche, Río Negro, R8402AGP, Argentina.,Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, C1033AAJ, Argentina
| | - Fabián José Bonetto
- Laboratorio de Cavitación y Biotecnología, Centro Atómico Bariloche, Río Negro, R8402AGP, Argentina.,Instituto Balseiro, Universidad Nacional de Cuyo/Comisión Nacional de Energía Atómica, Bariloche, Río Negro, R8402AGP, Argentina.,Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, C1033AAJ, Argentina
| | - Mariela Inés Bellotti
- Laboratorio de Cavitación y Biotecnología, Centro Atómico Bariloche, Río Negro, R8402AGP, Argentina
| |
Collapse
|
|
28
|
Okunowo AA, Daramola ES, Soibi-Harry AP, Ezenwankwo FC, Kuku JO, Okunade KS, Anorlu RI. Women's knowledge of cervical cancer and uptake of Pap smear testing and the factors influencing it in a Nigerian tertiary hospital. JOURNAL OF CANCER RESEARCH AND PRACTICE 2018. [DOI: 10.1016/j.jcrpr.2018.02.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
|
29
|
Habibi D, Heydari S, Faraji A, Keypour H, Mahmoudabadi M. A green and facile approach for the synthesis of N-monosubstituted ureas in water: Pd catalyzed reaction of arylcyanamides (an unexpected behavior of electron withdrawing groups). Polyhedron 2018. [DOI: 10.1016/j.poly.2018.05.049] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
|
30
|
Vin-Raviv N, Akinyemiju TF, Galea S, Bovbjerg DH. Sleep disorder diagnoses and clinical outcomes among hospitalized breast cancer patients: a nationwide inpatient sample study. Support Care Cancer 2018; 26:1833-1840. [PMID: 29264658 DOI: 10.1007/s00520-017-4012-1] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2017] [Accepted: 12/05/2017] [Indexed: 12/22/2022]
Abstract
PURPOSE Sleep disturbances are recognized as a problem for many cancer patients, but little is known about the prevalence of sleep disorders among women hospitalized with breast cancer, or their relationship to in-hospital outcomes. The present study represents a first step toward determining the clinical significance of sleep disorders for hospitalized breast cancer patients with regard to complications, length of hospital stay, and mortality. METHODS The relationships between sleep disorders and in-hospital outcomes among 84,424 hospitalized breast cancer patients were examined. This study analyzed the Nationwide Inpatient Sample (NIS) database (2007 to 2011) for all women ages 40 years and older with a primary discharge diagnosis of breast cancer and a secondary discharge diagnosis of sleep disorder. Odds ratios, estimates, and 95% confidence intervals were computed using multivariable regression adjusting for age, comorbidities, race, cancer stage, income, insurance type, residential region, year of discharge, and surgical treatment type. RESULTS Among women hospitalized with a primary diagnosis of breast cancer, 2% (n = 1807) also received a diagnosis of a sleep disorder during hospitalization, the majority of which were sleep-related breathing disorders (n = 1274). Although there was no significant association between having a diagnosis of a sleep disorder and in-hospital mortality, patients with a sleep disorder were more likely to also experience complications (OR = 1.58, 95% CI 1.29-1.34) and have longer hospital stays (mean = 0.44 days longer, 95% CI 0.25-0.63). CONCLUSION Hospitalized breast cancer patients with a sleep disorder were more likely to experience clinical complications and stay longer in the hospital. It remains an open and important question for future research whether interventions to improve sleep during hospitalization would help to improve clinical outcomes.
Collapse
Affiliation(s)
- Neomi Vin-Raviv
- School of Social Work, College of Health and Human Sciences, Colorado State University, Fort Collins, CO, USA.
- University of Northern Colorado Cancer Rehabilitation Institute, School of Sport and Exercise Science, University of Northern Colorado, Greeley, CO, USA.
| | - T F Akinyemiju
- Department of Epidemiology, University of Alabama School of Public Health, Birmingham, AL, USA
| | - S Galea
- Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA
| | - D H Bovbjerg
- University of Pittsburgh, and the UPMC-Hillman Cancer Center, Division Departments of Psychiatry, Psychology, Behavioral & Community Health Sciences, and Health & Community Systems, Pittsburgh, PA, USA
| |
Collapse
|
|
31
|
Park SY, Zacharias C, Harrison C, Fan RE, Kunder C, Hatami N, Giesel F, Ghanouni P, Daniel B, Loening AM, Sonn GA, Iagaru A. Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer. Radiology 2018; 288:495-505. [PMID: 29786490 DOI: 10.1148/radiol.2018172232] [Citation(s) in RCA: 79] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Purpose To report the results of dual-time-point gallium 68 (68Ga) prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET)/magnetic resonance (MR) imaging prior to prostatectomy in patients with intermediate- or high-risk cancer. Materials and Methods Thirty-three men who underwent conventional imaging as clinically indicated and who were scheduled for radical prostatectomy with pelvic lymph node dissection were recruited for this study. A mean dose of 4.1 mCi ± 0.7 (151.7 MBq ± 25.9) of 68Ga-PSMA-11 was administered. Whole-body images were acquired starting 41-61 minutes after injection by using a GE SIGNA PET/MR imaging unit, followed by an additional pelvic PET/MR imaging acquisition at 87-125 minutes after injection. PET/MR imaging findings were compared with findings at multiparametric MR imaging (including diffusion-weighted imaging, T2-weighted imaging, and dynamic contrast material-enhanced imaging) and were correlated with results of final whole-mount pathologic examination and pelvic nodal dissection to yield sensitivity and specificity. Dual-time-point metabolic parameters (eg, maximum standardized uptake value [SUVmax]) were compared by using a paired t test and were correlated with clinical and histopathologic variables including prostate-specific antigen level, Gleason score, and tumor volume. Results Prostate cancer was seen at 68Ga-PSMA-11 PET in all 33 patients, whereas multiparametric MR imaging depicted Prostate Imaging Reporting and Data System (PI-RADS) 4 or 5 lesions in 26 patients and PI-RADS 3 lesions in four patients. Focal uptake was seen in the pelvic lymph nodes in five patients. Pathologic examination confirmed prostate cancer in all patients, as well as nodal metastasis in three. All patients with normal pelvic nodes in PET/MR imaging had no metastases at pathologic examination. The accumulation of 68Ga-PSMA-11 increased at later acquisition times, with higher mean SUVmax (15.3 vs 12.3, P < .001). One additional prostate cancer was identified only at delayed imaging. Conclusion This study found that 68Ga-PSMA-11 PET can be used to identify prostate cancer, while MR imaging provides detailed anatomic guidance. Hence, 68Ga-PSMA-11 PET/MR imaging provides valuable diagnostic information and may inform the need for and extent of pelvic node dissection.
Collapse
Affiliation(s)
- Sonya Youngju Park
- From the Division of Nuclear Medicine and Molecular Imaging (S.Y.P., C.Z., C.H., N.H., A.I.) and Departments of Urology (R.E.F., G.A.S.), Pathology (C.K.), and Radiology (P.G., B.D., A.M.L.), Stanford University Medical Center, 300 Pasteur Dr, Room H-2200, Stanford, CA 94305; and Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany (F.G.)
| | - Claudia Zacharias
- From the Division of Nuclear Medicine and Molecular Imaging (S.Y.P., C.Z., C.H., N.H., A.I.) and Departments of Urology (R.E.F., G.A.S.), Pathology (C.K.), and Radiology (P.G., B.D., A.M.L.), Stanford University Medical Center, 300 Pasteur Dr, Room H-2200, Stanford, CA 94305; and Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany (F.G.)
| | - Caitlyn Harrison
- From the Division of Nuclear Medicine and Molecular Imaging (S.Y.P., C.Z., C.H., N.H., A.I.) and Departments of Urology (R.E.F., G.A.S.), Pathology (C.K.), and Radiology (P.G., B.D., A.M.L.), Stanford University Medical Center, 300 Pasteur Dr, Room H-2200, Stanford, CA 94305; and Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany (F.G.)
| | - Richard E Fan
- From the Division of Nuclear Medicine and Molecular Imaging (S.Y.P., C.Z., C.H., N.H., A.I.) and Departments of Urology (R.E.F., G.A.S.), Pathology (C.K.), and Radiology (P.G., B.D., A.M.L.), Stanford University Medical Center, 300 Pasteur Dr, Room H-2200, Stanford, CA 94305; and Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany (F.G.)
| | - Christian Kunder
- From the Division of Nuclear Medicine and Molecular Imaging (S.Y.P., C.Z., C.H., N.H., A.I.) and Departments of Urology (R.E.F., G.A.S.), Pathology (C.K.), and Radiology (P.G., B.D., A.M.L.), Stanford University Medical Center, 300 Pasteur Dr, Room H-2200, Stanford, CA 94305; and Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany (F.G.)
| | - Negin Hatami
- From the Division of Nuclear Medicine and Molecular Imaging (S.Y.P., C.Z., C.H., N.H., A.I.) and Departments of Urology (R.E.F., G.A.S.), Pathology (C.K.), and Radiology (P.G., B.D., A.M.L.), Stanford University Medical Center, 300 Pasteur Dr, Room H-2200, Stanford, CA 94305; and Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany (F.G.)
| | - Frederik Giesel
- From the Division of Nuclear Medicine and Molecular Imaging (S.Y.P., C.Z., C.H., N.H., A.I.) and Departments of Urology (R.E.F., G.A.S.), Pathology (C.K.), and Radiology (P.G., B.D., A.M.L.), Stanford University Medical Center, 300 Pasteur Dr, Room H-2200, Stanford, CA 94305; and Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany (F.G.)
| | - Pejman Ghanouni
- From the Division of Nuclear Medicine and Molecular Imaging (S.Y.P., C.Z., C.H., N.H., A.I.) and Departments of Urology (R.E.F., G.A.S.), Pathology (C.K.), and Radiology (P.G., B.D., A.M.L.), Stanford University Medical Center, 300 Pasteur Dr, Room H-2200, Stanford, CA 94305; and Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany (F.G.)
| | - Bruce Daniel
- From the Division of Nuclear Medicine and Molecular Imaging (S.Y.P., C.Z., C.H., N.H., A.I.) and Departments of Urology (R.E.F., G.A.S.), Pathology (C.K.), and Radiology (P.G., B.D., A.M.L.), Stanford University Medical Center, 300 Pasteur Dr, Room H-2200, Stanford, CA 94305; and Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany (F.G.)
| | - Andreas M Loening
- From the Division of Nuclear Medicine and Molecular Imaging (S.Y.P., C.Z., C.H., N.H., A.I.) and Departments of Urology (R.E.F., G.A.S.), Pathology (C.K.), and Radiology (P.G., B.D., A.M.L.), Stanford University Medical Center, 300 Pasteur Dr, Room H-2200, Stanford, CA 94305; and Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany (F.G.)
| | - Geoffrey A Sonn
- From the Division of Nuclear Medicine and Molecular Imaging (S.Y.P., C.Z., C.H., N.H., A.I.) and Departments of Urology (R.E.F., G.A.S.), Pathology (C.K.), and Radiology (P.G., B.D., A.M.L.), Stanford University Medical Center, 300 Pasteur Dr, Room H-2200, Stanford, CA 94305; and Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany (F.G.)
| | - Andrei Iagaru
- From the Division of Nuclear Medicine and Molecular Imaging (S.Y.P., C.Z., C.H., N.H., A.I.) and Departments of Urology (R.E.F., G.A.S.), Pathology (C.K.), and Radiology (P.G., B.D., A.M.L.), Stanford University Medical Center, 300 Pasteur Dr, Room H-2200, Stanford, CA 94305; and Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany (F.G.)
| |
Collapse
|
|
32
|
Omar Mostafa M, Makram Botros J, Sayed Khaleel AM. Effect of Dexmedetomidine Versus Nalbuphine as an Adjuvant on Paravertebral Block to Manage Postoperative Pain After Mastectomies. Anesth Pain Med 2018; 8:e13308. [PMID: 30027066 PMCID: PMC6045777 DOI: 10.5812/aapm.13308] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2017] [Revised: 03/27/2018] [Accepted: 03/29/2018] [Indexed: 12/13/2022] Open
Abstract
Background and Objective Breast cancer is the commonest cancer in women worldwide. Many patients are frequently admitted to the operating theaters for mastectomies. Thoracic paravertebral block (PVB) is increasingly used as an effective means for post-operative pain relief. The present study aimed at evaluating the effectiveness and safety of dexmedetomidine and nalbuphine as an adjuvant to bupivacaine local anesthetic in thoracic paravertebral block in breast cancer surgeries. Methods A total of 60 female patients aged 18 to 78 were included in the study, and ASA I, II, III were scheduled for mastectomy. These patients were unsystematically assigned into three 20-member groups: group PB received bupivacaine (0.3 mL/ kg) + 1 mL (0.9% sodium chloride) normal saline; group PBD received bupivacaine (0.3 mL/kg) + dexmedetomidine 1 μg/kg; and Group PBN received bupivacaine (0.3 mL/kg) and 10 mg (1 mL) nalbuphine. Demographic data, intraoperative SPO2, ETCO2, HR, SBP and DBP, pain scores (at rest and movement), and sedation scores were recorded every 30 minutes during the initial 2 hours and 4, 8, 24, and 48 hours from T0. Also, postoperative tramadol consumption, the time to the first analgesic request, and any complications were also recorded. Results There were no statistically significant differences among the three groups regarding demographic data, SPO2, ETCO2, HR, SBP and DBP intraoperatively. Moreover, no significant difference was found in HR, SBP and DBP postoperatively. Postoperative pain scores were significantly higher in group BP, whether at rest or movement. The sedation was significantly higher in PBD group in the first 12 hours postoperatively. There was a significantly lower postoperative tramadol consumption in PBN group and a significantly longer time to the first analgesic request than other groups. No complications were reported in any group. Conclusions Addition of nalbuphine 10 mg as an adjuvant to bupivacaine local anesthetic in PVB improved the quality of the block and decreased postoperative analgesic requirements than the bupivacaine only group and dexmedetomidine and bupivacaine group. However, adding dexmedetomidine to bupivacaine increased the time to the first analgesic request and more sedation than bupivacaine and bupivacaine and nalbuphine.
Collapse
Affiliation(s)
| | - Joseph Makram Botros
- Anesthesiology, Faculty of Medicine, Fayoum University, Faiyum, Egypt
- Corresponding author: Joseph Makram Botros, Lecturer of Anesthesiology, Faculty of Medicine, Fayoum University, Faiyum, Egypt. E-mail:
| | | |
Collapse
|
|
33
|
Epidemiological Aspects in Lip Tumors in Oltenia Region of Romania During 2012-2016. CURRENT HEALTH SCIENCES JOURNAL 2018; 44:39-47. [PMID: 30622754 PMCID: PMC6295190 DOI: 10.12865/chsj.44.01.07] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/04/2018] [Accepted: 03/21/2018] [Indexed: 12/02/2022]
Abstract
Purpose. The objective of this study was to review lip tumor diagnosed subjects from Oltenia
region, in the past 5 years according to gender, age, home environment,
profession, geographic area, smoking habit, associated diseases, tumor location,
macroscopic aspect and histological type. Material and Methods. The study was
done at the Oral and Maxillo-Facial Clinic of the Emergency Clinical County
Hospital of Craiova, and involved the analysis of patient file records, surgical
registers, histopathological bulletins, from 2012-2016. Results. Of the 175
subjects included in this study, all of them diagnosed with lip tumor pathology,
109 (62.29%) were men, and 66 (37.71%) were women, all of
them with ages between 6 and 92 years, with a mean age of 61 years. Distribution
of study participants according to the home residence showed that majority of
the subjects lived in rural area. The most frequently localization of lip tumors
in study participants was at the lower lip-140 cases (80%), than at
the upper lip-35 cases (20%).According to histological
characteristics, distribution of the malignant lip tumors was
87.39%-squamous cell carcinoma (SCC), 5.41%-basal cell
carcinoma (BCC) and 7.20%-other type of tumors. Conclusions. The
lower lip was the most affected, by lip cancer, and squamous cell carcinoma
represents the most frequently histological type of these tumors.
Collapse
|
|
34
|
Cossu G, Saba L, Minerba L, Mascalchi M. Colorectal Cancer Screening: The Role of Psychological, Social and Background Factors in Decision-making Process. Clin Pract Epidemiol Ment Health 2018; 14:63-69. [PMID: 29643929 PMCID: PMC5872199 DOI: 10.2174/1745017901814010063] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2017] [Revised: 02/08/2018] [Accepted: 02/19/2018] [Indexed: 12/27/2022]
Abstract
Since ColoRectal Cancer (CRC) remains the third cause of cancer death in the world, a better understanding of the reasons underlying poor adherence to and delay in undergoing CRC screening programs is important. CRC screening decision-making process can be conceptualized as the relationship between intention and behavior and needs to be investigated including the impact on patients' decision of a broad range of psychological factors and personal predisposition as fear of a positive screening test, poor understanding of the procedure, psychological distress, anxiety, anticipation of pain, feelings of embarrassment and vulnerability. Also socioeconomic, ethnic and sociological influences, and organizational barriers have been identified as factors influencing CRC screening adherence. Decision-making process can finally be influenced by the healthcare background in which the intervention is promoted and screening programs are carried out. However, there is still a gap on the scientific knowledge about the influences of diverse elements on screening adherence and this deserves further investigations in order to carry out more focused and effective prevention programs.
Collapse
Affiliation(s)
- Giulia Cossu
- Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy
| | - Luca Saba
- Department of Radiology, AOU, University of Cagliari, Cagliari, Italy
| | - Luigi Minerba
- Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy
| | - Mario Mascalchi
- Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy
| |
Collapse
|
|
35
|
Thorsteinsdottir B, Hickson LJ, Ramar P, Reinalda M, Krueger NW, Crowson CS, Rule AD, Takahashi PY, Chaudhry R, Tulledge-Scheitel SM, Tilburt JC, Williams AW, Albright RC, Meier SK, Shah ND. High rates of cancer screening among dialysis patients seen in primary care a cohort study. Prev Med Rep 2018; 10:176-183. [PMID: 29868364 PMCID: PMC5984226 DOI: 10.1016/j.pmedr.2018.03.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2017] [Revised: 02/09/2018] [Accepted: 03/09/2018] [Indexed: 11/22/2022] Open
Abstract
Routine preventive cancer screening is not recommended for patients with end-stage renal disease (ESRD)1 due to their limited life expectancy. The current extent of cancer screening in this population is unknown. Primary care (PC) reminder systems or performance incentives may encourage indiscriminate cancer screening. We compared rates of cancer screening in patients with ESRD, with and without PC visits. This is a retrospective cohort study using United States Renal Data System (USRDS) billing data and electronic medical record data. Patients aged ≥18 years starting dialysis from 2001 to 2008, Midwest regional dialysis network were categorized with or without a PC visit (defined as an office visit in family practice, internal medicine, pediatrics, geriatrics or preventive medicine during the first two years of dialysis). Cancer screening was based on Current Procedural Terminology codes in USRDS. We identified 2512 incident dialysis patients (60% men, median age 65y). Cancer screening rates were more frequent among those seen in PC: 38% vs 19% (P = 0.0002), for breast; 18% vs 10% (P = 0.047) for cervical; 13% versus 8% (P = 0.024) for prostate; and 18% vs 9% (P = 0.0002) for colon cancer. Multivariable analyses found that those with PC were more likely to be screened after adjusting for age, sex, and comorbidities. In our practice, cancer screening rates among chronic dialysis patients are lower than those previously reported for our general population (64% for breast cancer). However, a sizeable proportion of our ESRD population does receive cancer screening, especially those still seen in primary care.
Dialysis patients have relatively high rates of cancer screening. Patients seen in primary care were more likely to get breast and colon ca screening. Half of women over age 65 received breast cancer screening within two years.
Collapse
Affiliation(s)
- Bjorg Thorsteinsdottir
- Division of Primary Care Internal Medicine, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.,Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, 200 First Street SW, Rochester, MN, USA
| | - LaTonya J Hickson
- Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.,Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, 200 First Street SW, Rochester, MN, USA
| | - Priya Ramar
- Division of Health Care Policy & Research, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.,Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, 200 First Street SW, Rochester, MN, USA
| | - Megan Reinalda
- Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.,Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, 200 First Street SW, Rochester, MN, USA
| | - Nicholas W Krueger
- Division of Health Care Policy & Research, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.,Carnrite Group, 10330-DD Lake Rd, Houston, TX 77070, USA
| | - Cynthia S Crowson
- Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.,Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, 200 First Street SW, Rochester, MN, USA
| | - Andrew D Rule
- Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.,Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, 200 First Street SW, Rochester, MN, USA
| | - Paul Y Takahashi
- Division of Primary Care Internal Medicine, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA
| | - Rajeev Chaudhry
- Division of Primary Care Internal Medicine, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA
| | - Sidna M Tulledge-Scheitel
- Division of Primary Care Internal Medicine, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA
| | - Jon C Tilburt
- Division of General Internal Medicine, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA
| | - Amy W Williams
- Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA
| | - Robert C Albright
- Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA
| | - Sarah K Meier
- Division of Health Care Policy & Research, Mayo Clinic, 200 First Street SW, Rochester, MN, USA
| | - Nilay D Shah
- Division of Health Care Policy & Research, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.,Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, 200 First Street SW, Rochester, MN, USA
| |
Collapse
|
|
36
|
Anwar SL, Tampubolon G, Van Hemelrijck M, Hutajulu SH, Watkins J, Wulaningsih W. Determinants of cancer screening awareness and participation among Indonesian women. BMC Cancer 2018; 18:208. [PMID: 29506486 PMCID: PMC5838961 DOI: 10.1186/s12885-018-4125-z] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2017] [Accepted: 02/12/2018] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Cancer screening awareness and participation may be lower in low- and middle-income countries that lack established national screening programmes compared with those that do. We evaluated potential determinants of awareness about and participation in breast and cervical cancer screening, and breast self-examination (BSE) in women using survey data from Indonesia. METHODS From the fifth Indonesian Family Life Survey (2014-2015), a total of 5397 women aged 40 and older without any history of cancer who responded to questionnaires concerning Pap smears, mammography, and BSE were included. Multilevel modelling was used to assess potential determinants in relation to awareness about Pap smears and mammography, and participation in Pap smears and BSE practice. Multivariable analyses were performed to identify independent predictors of cancer screening. RESULTS Of the 5397 respondents, 1058 (20%) women were aware of Pap smears, of which 297 had never had the procedure. Only 251 (5%) participants were aware of mammography. A total of 605 (12%) of women reported they performed BSE. Higher education and household expenditure were consistently associated with higher odds of awareness about Pap smears and mammography (e.g. odds ratio [OR] of being aware of Pap smear and mammography: 7.82 (95% CI: 6.30-9.70) and 7.70 (6.19-9.58), respectively, for high school graduates compared to women with less educational attainment in the multivariable models), and participation in Pap smears and BSE. We also identified enabling factors linked with greater cancer screening awareness and participation, including health insurance, shorter distance to health services, and social participation. CONCLUSION There are socioeconomic disparities in cancer screening awareness and participation among Indonesian women. Our findings may help inform targeted health promotion and screening for cancer in the presence of limited resources.
Collapse
Affiliation(s)
- Sumadi L. Anwar
- Division of Surgical Oncology Department of Surgery, Faculty of Medicine Universitas Gadjah Mada, Yogyakarta, 55281 Indonesia
- PILAR Research and Education, 20 Station Road, Cambridge, CB1 2JD UK
| | - Gindo Tampubolon
- Cathie Marsh Institute for Social Research, University of Manchester, M13 9PL, Manchester, UK
| | - Mieke Van Hemelrijck
- Translational Oncology and Urology Research, King’s College London, London, SE1 9RT UK
| | - Susanna H. Hutajulu
- Division of Medical Haematology and Oncology Department of Internal Medicine, Faculty of Medicine Universitas Gadjah Mada, Yogyakarta, 55281 Indonesia
| | - Johnathan Watkins
- PILAR Research and Education, 20 Station Road, Cambridge, CB1 2JD UK
| | - Wahyu Wulaningsih
- PILAR Research and Education, 20 Station Road, Cambridge, CB1 2JD UK
- MRC Unit for Lifelong Health and Ageing, University College London, Place London WC1B 5JU, Bedford, 33 UK
| | - for the PILAR Research Network
- Division of Surgical Oncology Department of Surgery, Faculty of Medicine Universitas Gadjah Mada, Yogyakarta, 55281 Indonesia
- PILAR Research and Education, 20 Station Road, Cambridge, CB1 2JD UK
- Cathie Marsh Institute for Social Research, University of Manchester, M13 9PL, Manchester, UK
- Translational Oncology and Urology Research, King’s College London, London, SE1 9RT UK
- Division of Medical Haematology and Oncology Department of Internal Medicine, Faculty of Medicine Universitas Gadjah Mada, Yogyakarta, 55281 Indonesia
- MRC Unit for Lifelong Health and Ageing, University College London, Place London WC1B 5JU, Bedford, 33 UK
| |
Collapse
|
|
37
|
Guo J, Wu Y, Yang L, Du J, Gong K, Chen W, Dai J, Li X, Xi S. Repression of YAP by NCTD disrupts NSCLC progression. Oncotarget 2018; 8:2307-2319. [PMID: 27903989 PMCID: PMC5356801 DOI: 10.18632/oncotarget.13668] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2016] [Accepted: 11/21/2016] [Indexed: 11/25/2022] Open
Abstract
The efficacy of available lung cancer therapeutic interference is significantly limited by various resistance mechanisms to those drugs. Activation of the oncogene YAP underlying the initiation, progression, and metastasis of lung cancer associates with poor prognosis and confers drug resistance against targeted therapy. In this study, we evaluated the specificity of norcantharidin (NCTD) in repressing YAP to inhibit non-small cell lung carcinoma (NSCLC) progression. Our study revealed that YAP signal pathways were aberrantly activated in lung cancer tissues and cells which rendered more proliferative and invasive phenotypes to human lung cancer cells. We confirmed that NCTD specifically repressed YAP signaling pathway to interfere the YAP-mediated non-small cell lung carcinoma progression and metastasis via arresting cell cycle, enhancing apoptosis and inducing senescence. We also found NCTD-mediated repression of YAP decreased epithelial-to-mesenchymal transition (EMT) and reduced the motile and invasive cellular phenotype in vitro via enhancing E-cadherin and decreasing fibronectin/vimentin. Mechanistic investigations revealed that NCTD transcriptionally downregulated YAP and post-translationally modulated the subcellular redistribution of YAP between nucleus and cytoplasm. Collectively, our results indicated that NCTD is a novel therapeutic drug candidate for NSCLC which specifically and sensitively target YAP signal pathway.
Collapse
Affiliation(s)
- Jiwei Guo
- Cancer Research Institute, Binzhou Medical University Hospital, Binzhou 256603, P.R. China
| | - Yan Wu
- Cancer Research Institute, Binzhou Medical University Hospital, Binzhou 256603, P.R. China
| | - Lijuan Yang
- Cancer Research Institute, Binzhou Medical University Hospital, Binzhou 256603, P.R. China
| | - Jing Du
- Cancer Research Institute, Binzhou Medical University Hospital, Binzhou 256603, P.R. China
| | - Kaikai Gong
- Cancer Research Institute, Binzhou Medical University Hospital, Binzhou 256603, P.R. China
| | - Weiwei Chen
- Cancer Research Institute, Binzhou Medical University Hospital, Binzhou 256603, P.R. China
| | - Juanjuan Dai
- Cancer Research Institute, Binzhou Medical University Hospital, Binzhou 256603, P.R. China
| | - XueLin Li
- Cancer Research Institute, Binzhou Medical University Hospital, Binzhou 256603, P.R. China
| | - Sichuan Xi
- Cancer Research Institute, Binzhou Medical University Hospital, Binzhou 256603, P.R. China
| |
Collapse
|
|
38
|
Sandbhor Gaikwad P, Banerjee R. Advances in point-of-care diagnostic devices in cancers. Analyst 2018; 143:1326-1348. [DOI: 10.1039/c7an01771e] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The early diagnosis and monitoring of the progress of cancers are limited due to the lack of adequate screening tools.
Collapse
Affiliation(s)
- Puja Sandbhor Gaikwad
- Research Scholar
- Department of Biosciences and Bioengineering
- Indian Institute of Technology Bombay
- Mumbai
- India-400076
| | - Rinti Banerjee
- Department of Biosciences and Bioengineering
- Indian Institute of Technology Bombay
- Mumbai
- India-400076
| |
Collapse
|
|
39
|
Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7. Eur J Med Chem 2018; 143:1807-1825. [DOI: 10.1016/j.ejmech.2017.10.075] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2017] [Revised: 09/28/2017] [Accepted: 10/28/2017] [Indexed: 01/16/2023]
|
|
40
|
Guedaoura S, Pelletier S, Foulkes W, Hamet P, Simard J, Wong N, El Haffaf Z, Chiquette J, Dorval M. No evidence of excessive cancer screening in female noncarriers from BRCA1/2 mutation-positive families. Curr Oncol 2017; 24:352-359. [PMID: 29270046 PMCID: PMC5736476 DOI: 10.3747/co.24.3759] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
BACKGROUND In families with a proven BRCA1/2 mutation, women not carrying the familial mutation should follow the cancer screening recommendations applying to women in the general population. In the present study, we evaluated the cancer screening practices of unaffected noncarriers from families with a proven BRCA mutation, and we assessed the role of family history in their screening practices. METHODS Self-report data were provided retrospectively by 220 unaffected female noncarriers for periods of up to 10 years (mean: 4.3 years) since disclosure of their BRCA1/2 genetic test result. A ratio for the annual frequency of breast and ovarian cancer screening exams (mammography, breast ultrasonography, breast magnetic resonance imaging, transvaginal or pelvic ultrasound, cancer antigen 125 testing) was calculated as number of screening exams divided by the number of years in the individual observation period. RESULTS The annual average for mammography exams was 0.15, 0.4, 0.56, and 0.71 in women 30-39, 40-49, 50-59, and 60-69 years of age respectively. The uptake of other breast and ovarian cancer screening exams was very low. Mammography and breast ultrasonography and magnetic resonance imaging were generally more frequent among participants with at least 1 first-degree relative affected by breast cancer. CONCLUSIONS In most noncarriers, screening practices are consistent with the guidelines concerning women in the general population. When noncarriers adopt screening behaviours that are different from those that would be expected for average-risk women, those behaviours are influenced by their familial cancer history. IMPACT Decision tools might help female noncarriers to be involved in their follow-up in accordance with their genetic status and their family history, while taking into account the benefits and disadvantages of cancer screening.
Collapse
Affiliation(s)
- S. Guedaoura
- Faculté de pharmacie, Université Laval, Québec
- Centre de recherche du chu de Québec-Université Laval, Québec
| | - S. Pelletier
- Centre de recherche du chu de Québec-Université Laval, Québec
| | - W.D. Foulkes
- Departments of Human Genetics and Oncology, McGill University, Montreal
- Sir Mortimer B. Davis Jewish General Hospital, Montreal
| | - P. Hamet
- Faculté de médecine, Université de Montréal, Montréal
- Service de médecine génique, chum, Montréal
| | - J. Simard
- Centre de recherche du chu de Québec-Université Laval, Québec
- Faculté de médecine, Université Laval, Québec; and
| | - N. Wong
- Sir Mortimer B. Davis Jewish General Hospital, Montreal
| | - Z. El Haffaf
- Faculté de médecine, Université de Montréal, Montréal
- Faculté de médecine, Université Laval, Québec; and
| | - J. Chiquette
- Centre de recherche du chu de Québec-Université Laval, Québec
- Faculté de médecine, Université Laval, Québec; and
- Centre des maladies du sein Deschênes–Fabia, chu de Québec–Université Laval, Québec
| | - M. Dorval
- Faculté de pharmacie, Université Laval, Québec
- Centre de recherche du chu de Québec-Université Laval, Québec
- Centre des maladies du sein Deschênes–Fabia, chu de Québec–Université Laval, Québec
| |
Collapse
|
|
41
|
Xu CH, Wang W, Lin Y, Qian LH, Zhang XW, Wang QB, Yu LK. Diagnostic and prognostic value of serum periostin in patients with non-small cell lung cancer. Oncotarget 2017; 8:18746-18753. [PMID: 27816968 PMCID: PMC5386644 DOI: 10.18632/oncotarget.13004] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2016] [Accepted: 10/26/2016] [Indexed: 11/25/2022] Open
Abstract
The periostin protein is expressed in a variety of human malignancies. The aim of this study was to explore the diagnostic and prognostic value of serum periostin levels in patients with non-small cell lung cancer (NSCLC). We measured serum periostin levels by ELISA in 296 NSCLC patients, 120 benign lung diseases (BLD) patients and 160 healthy controls. The levels of serum periostin in NSCLC patients were significantly elevated compared with those in healthy controls (P < 0.001) and BLD patients (P < 0.001). Using a cutoff value of 30.87 ng/ml, the sensitivity and specificity of periostin in differentiating between NSCLC patients and BLD patients, and between NSCLC patients and healthy controls was, 48.6 and 91.7%, and 51.4 and 97.5%, respectively. Kaplan-Meier log rank analysis revealed that the higher serum periostin levels group had a poorer progression-free survival (PFS) and overall survival (OS) compared with lower periostin group (P = 0.024, P = 0.015, respectively). Further univariate and multivariate Cox regression analysis showed that serum periostin was an independent risk factor of prognosis of NSCLC patients. In conclusion, our study suggests that serum periostin could be considered as a diagnostic and prognostic marker for NSCLC patients.
Collapse
Affiliation(s)
- Chun-Hua Xu
- Endoscopic Center of Nanjing Chest Hospital, Nanjing, Jiangsu 210029, China.,Clinical Center of Nanjing Respiratory Diseases and Imaging, Nanjing, Jiangsu 210029, China
| | - Wei Wang
- Endoscopic Center of Nanjing Chest Hospital, Nanjing, Jiangsu 210029, China.,Clinical Center of Nanjing Respiratory Diseases and Imaging, Nanjing, Jiangsu 210029, China
| | - Yong Lin
- Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing, Jiangsu 210029, China
| | - Li-Hua Qian
- Department of Respiratory Medicine, Nanjing Pukou Central Hospital, Nanjing, Jiangsu 211800, China
| | - Xiu-Wei Zhang
- Department of Respiratory Medicine, Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, Jiangsu 211100, China
| | - Qing-Bo Wang
- Department of Geriatrics Medicine, Nanjing Second Hospital, Nanjing, Jiangsu 210003, China
| | - Li-Ke Yu
- Endoscopic Center of Nanjing Chest Hospital, Nanjing, Jiangsu 210029, China
| |
Collapse
|
|
42
|
Fontenot PA, Nehra A, Parker W, Wyre H, Mirza M, Duchene DA, Holzbeierlein J, Thrasher JB, Van Veldhuizen P, Lee EK. Metastatic prostate cancer in the modern era of PSA screening. Int Braz J Urol 2017; 43:416-421. [PMID: 28338310 PMCID: PMC5462131 DOI: 10.1590/s1677-5538.ibju.2016.0340] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2016] [Accepted: 12/20/2016] [Indexed: 11/23/2022] Open
Abstract
Introduction To characterize initial presentation and PSA screening status in a contemporary cohort of men treated for metastatic prostate cancer at our institution. Materials and methods We reviewed records of 160 men treated for metastatic prostate cancer between 2008-2014 and assessed initial presentation, categorizing patients into four groups. Groups 1 and 2 presented with localized disease and received treatment. These men suffered biochemical recurrence late (>1 year) or earlier (<1 year), respectively, and developed metastases. Groups 3 and 4 had asymptomatic and symptomatic metastases at the outset of their diagnosis. Patients with a first PSA at age 55 or younger were considered to have guideline-directed screening. Results Complete records were available on 157 men for initial presentation and 155 men for PSA screening. Groups 1, 2, 3 and 4 included 27 (17%), 7 (5%), 69 (44%) and 54 (34%) patients, respectively. Twenty (13%) patients received guideline-directed PSA screening, 5/155 (3%) patients presented with metastases prior to age 55 with their first PSA, and 130/155 (84%) had their first PSA after age 55, of which 122/130 (94%) had metastasis at the time of diagnosis. Conclusion Despite widespread screening, most men treated for metastatic prostate cancer at our institution presented with metastases rather than progressed after definitive treatment. Furthermore, 25 (16%) patients received guideline-directed PSA screening at or before age 55. These data highlight that, despite mass screening efforts, patients treated for incurable disease at our institution may not have been a result of a failed screening test, but a failure to be screened.
Collapse
Affiliation(s)
- Philip A Fontenot
- Department of Urology, University of Kansas Medical Center, Kansas City, Kansas, USA
| | - Avinash Nehra
- Department of Urology, University of Kansas Medical Center, Kansas City, Kansas, USA
| | - William Parker
- Department of Urology, University of Kansas Medical Center, Kansas City, Kansas, USA
| | - Hadley Wyre
- Department of Urology, University of Kansas Medical Center, Kansas City, Kansas, USA
| | - Moben Mirza
- Department of Urology, University of Kansas Medical Center, Kansas City, Kansas, USA
| | - David A Duchene
- Department of Urology, University of Kansas Medical Center, Kansas City, Kansas, USA
| | - Jeffrey Holzbeierlein
- Department of Urology, University of Kansas Medical Center, Kansas City, Kansas, USA
| | | | - Peter Van Veldhuizen
- Division of Hematology/Oncology, University of Kansas Medical Center, Kansas City, Kansas, USA
| | - Eugene K Lee
- Department of Urology, University of Kansas Medical Center, Kansas City, Kansas, USA
| |
Collapse
|
|
43
|
Rezabeigi-davarani E, Khanjani N, Falahi M, Daneshi S, Iranpour A. Breast Self-examination and its Effective Factors Based on the Theory of Planned Behavior among Women in Kerman, Iran. JOURNAL OF EDUCATION AND COMMUNITY HEALTH 2017. [DOI: 10.21859/jech-03031] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
|
44
|
Jin LJ, Wen LY, Zhang YL, Li G, Sun P, Zhou X. Thoracic paravertebral regional anesthesia for pain relief in patients with breast cancer surgery. Medicine (Baltimore) 2017; 96:e8107. [PMID: 28953631 PMCID: PMC5626274 DOI: 10.1097/md.0000000000008107] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
BACKGROUND The present study aimed to assess the efficacy and safety of thoracic paravertebral regional anesthesia (TPVBRA) in patients with breast cancer surgery. METHODS In total, 72 patients undergoing breast cancer surgery were randomly divided into an intervention group and a control group; each group contained 36 subjects. Both groups received TPVBRA with 20 mL 0.25% bupivacaine. In addition, subjects in the intervention group also received an additional 1 μg/kg dexmedetomidine. Heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), pain intensity (measured by visual analogue scale, VAS), and analgesic consumption were assessed; adverse events were also recorded. RESULTS Significant differences were observed in HR (P < .05), SBP (P < .05), and DBP (P < .05) at the 30-minute point during surgery between the 2 groups. In addition, the time of the first administration of analgesia (P = .043) and the mean consumption of analgesic agents (P = .035) in the intervention group were much better than those in the control group. However, no significant differences in HR or VAS were found at any time point after surgery (P > .05). Furthermore, similar adverse events were detected in both groups (P > .05). CONCLUSION The results of this study showed that TPVBRA combined with bupivacaine and dexmedetomidine can enhance the duration and quality of analgesia without serious adverse events.
Collapse
Affiliation(s)
| | | | | | - Gang Li
- Department of Orthopaedics, The Affiliated Hongqi Hospital of Mudanjiang Medical University
| | - Ping Sun
- Department of Anatomy, Mudanjiang Medical University, Mudanjiang, China
| | | |
Collapse
|
|
45
|
Self-Assembling RADA16-I Peptide Hydrogel Scaffold Loaded with Tamoxifen for Breast Reconstruction. BIOMED RESEARCH INTERNATIONAL 2017; 2017:3656193. [PMID: 28691024 PMCID: PMC5485292 DOI: 10.1155/2017/3656193] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/05/2017] [Revised: 04/11/2017] [Accepted: 05/03/2017] [Indexed: 12/20/2022]
Abstract
More and more breast cancer patients prefer autologous fat tissue transfer following lumpectomy to maintain perfect female characteristics. However, the outcome was not satisfactory due to the transplanted fat absorption. In this study, we prepared two RADA16-I peptide scaffolds with and without tamoxifen. Both scaffolds were transparent, porous, and hemisphere-shaped. The hADSCs isolated from liposuction were attached to the scaffold. The growth inhibition of the hADSCs induced by TAM in 2-demensional (2D) culture was higher than that in TAM-loaded hydrogel scaffold 3D culture (P < 0.05); however, the same outcomes were not observed in MCF-7 cells. Correspondingly, the apoptosis of the hADSCs induced by TAM was significantly increased in 2D culture compared to that in scaffold 3D culture (P < 0.05). Yet the outcomes of the aoptosis in MCF-7 were contrary. Apoptosis-related protein Bcl-2 was involved in the process. In vivo experiments showed that both scaffolds formed a round mass after subcutaneous implantation and it retained its shape after being pressed slightly. The implantation had no effect on the weight and activity of the animals. The results suggested that TAM-loaded RADA16-I hydrogel scaffolds both provide support for hADSCs cells attachment/proliferation and retain cytotoxic effect on MCF-7 cells, which might be a promising therapeutic breast tissue following lumpectomy.
Collapse
|
|
46
|
Wang Z, Zong S, Wu L, Zhu D, Cui Y. SERS-Activated Platforms for Immunoassay: Probes, Encoding Methods, and Applications. Chem Rev 2017; 117:7910-7963. [DOI: 10.1021/acs.chemrev.7b00027] [Citation(s) in RCA: 368] [Impact Index Per Article: 46.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Zhuyuan Wang
- Advanced Photonics Center, Southeast University, Nanjing 210096, Jiangsu, China
| | - Shenfei Zong
- Advanced Photonics Center, Southeast University, Nanjing 210096, Jiangsu, China
| | - Lei Wu
- Advanced Photonics Center, Southeast University, Nanjing 210096, Jiangsu, China
| | - Dan Zhu
- Advanced Photonics Center, Southeast University, Nanjing 210096, Jiangsu, China
| | - Yiping Cui
- Advanced Photonics Center, Southeast University, Nanjing 210096, Jiangsu, China
| |
Collapse
|
|
47
|
Guilford K, McKinley E, Turner L. Breast Cancer Knowledge, Beliefs, and Screening Behaviors of College Women: Application of the Health Belief Model. AMERICAN JOURNAL OF HEALTH EDUCATION 2017. [DOI: 10.1080/19325037.2017.1316694] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
|
48
|
Nelson G, Wu M, Hinkel C, Krishna G, Funk T, Rosenberg J, Fahrig R. Improved targeting accuracy of lung tumor biopsies with scanning-beam digital x-ray tomosynthesis image guidance. Med Phys 2017; 43:6282. [PMID: 27908166 DOI: 10.1118/1.4966025] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
PURPOSE Electromagnetic navigation bronchoscopy (ENB) provides improved targeting accuracy during transbronchial biopsies of suspicious nodules. The greatest weakness of ENB-based guidance is the registration divergence that exists between the planning CT, acquired days or weeks before the intervention, and the patient on the table on the day of the intervention. Augmenting ENB guidance with real-time tomosynthesis imaging during the intervention could mitigate the divergence and further improve the yield of ENB-guided transbronchial biopsies. The real-time tomosynthesis prototype, the scanning-beam digital x-ray (SBDX) system, does not currently display images reconstructed by the iterative algorithm that was developed for this lung imaging application. A protocol using fiducial markers was therefore implemented to permit evaluation of potential improvements that would be provided by the SBDX system in a clinical setting. METHODS Ten 7 mm lesions (5 per side) were injected into the periphery of each of four preserved pig lungs. The lungs were then placed in a vacuum chamber that permitted simulation of realistic motion and deformation due to breathing. Standard clinical CT scans of the pig lung phantoms were acquired and reconstructed with isotropic resolution of 0.625 mm. Standard ENB-guided biopsy procedures including target identification, path planning, CT-to-lung registration and navigation to the lesion were carried out, and a fiducial marker was placed at the location at which a biopsy would have been acquired. The channel-to-target distance provided by the ENB system prior to fiducial placement was noted. The lung phantoms were then imaged using the SBDX system, and using high-resolution conebeam CT. The distance between the fiducial marker tip and the lesion was measured in SBDX images and in the gold-standard conebeam-CT images. The channel-to-target divergence predicted by the ENB system and measured in the SBDX images was compared to the gold standard to determine if improved targeting accuracy could be achieved using SBDX image guidance. RESULTS As expected, the ENB system showed poorer targeting accuracy for small peripheral nodules. Only 20 nodules of the 40 injected could be adequately reached using ENB guidance alone. The SBDX system was capable of visualizing these small lesions, and measured fiducial-to-target distances on SBDX agreed well with measurements in gold-standard conebeam-CT images (p = 0.0001). The correlation between gold-standard conebeam-CT distances and predicted fiducial-to-target distances provided by the ENB system was poor (p = 0.72), primarily due to inaccurate ENB CT-to-body registration and movement due to breathing. CONCLUSIONS The SBDX system permits visualization of small lung nodules, as well as accurate measurement of channel-to-target distances. Combined use of ENB with SBDX real-time image guidance could improve accuracy and yield of biopsies, particularly of those lesions located in the periphery of the lung.
Collapse
Affiliation(s)
- Geoff Nelson
- Department of Radiology, Stanford University, Stanford, California 94305
| | - Meng Wu
- Department of Radiology, Stanford University, Stanford, California 94305
| | - Cameron Hinkel
- Department of Radiology, Stanford University, Stanford, California 94305
| | - Ganesh Krishna
- Palo Alto Medical Foundation, Department of Medicine, University of California San Francisco, San Francisco, California 94143
| | - Tobias Funk
- Triple Ring Technologies, Inc., Newark, California 94560
| | - Jarrett Rosenberg
- Department of Radiology, Stanford University, Stanford, California 94305
| | - Rebecca Fahrig
- Department of Radiology, Stanford University, Stanford, California 94305
| |
Collapse
|
|
49
|
Zhang C, Yu G, Shen Y. The naturally occurring xanthone α-mangostin induces ROS-mediated cytotoxicity in non-small scale lung cancer cells. Saudi J Biol Sci 2017; 25:1090-1095. [PMID: 30174507 PMCID: PMC6116860 DOI: 10.1016/j.sjbs.2017.03.005] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2017] [Revised: 03/08/2017] [Accepted: 03/12/2017] [Indexed: 01/22/2023] Open
Abstract
Small cell lung cancer (NSCLC) accounts for 85% of total deaths globally, and recent studies indicate the increasing risks of NSCLC in China and South Asian countries. Hence, development of new therapeutics against NSCLC has been a major concern. α-Mangostin, a naturally occurring xanthone, found abundantly in pericarps of mangosteen fruit is well known for its medicinal importance. The anticancer properties of α-mangostin against several types of cancer are also well documented. But the mechanism of action of α-mangostin against lung cancer is not well understood and requires further investigation. Therefore in the present study, we explored the therapeutic potential of α-mangostin against A549 cells. Treatment of A549 cells with α-mangostin resulted in a dose-dependent loss of cell viability, while the non-malignant cells such as hPBMC and WI-38 remained unaffected. Further we observed that the ROS plays an important role in α-mangostin -induced apoptosis in A549 cells, and administration of N-acetyl cysteine significantly abrogates α-mangostin -mediated cytotoxicity in lung cancer cells. Overall, α-mangostin induces ROS-mediated cytotoxicity in NSCLC cells.
Collapse
Affiliation(s)
- Chunyun Zhang
- Department of Respiration, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, China
| | - Guifang Yu
- Department of Oncology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou 510700, China
| | - Yifeng Shen
- Guangzhou Wondfo Biotech Co., Ltd, Guangzhou 510663, China
| |
Collapse
|
|
50
|
Kobetz E, Seay J, Amofah A, Pierre L, Bispo JB, Trevil D, Gonzalez M, Poitevien M, Koru-Sengul T, Carrasquillo O. Mailed HPV self-sampling for cervical cancer screening among underserved minority women: study protocol for a randomized controlled trial. Trials 2017; 18:19. [PMID: 28086983 PMCID: PMC5237204 DOI: 10.1186/s13063-016-1721-6] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2016] [Accepted: 11/23/2016] [Indexed: 11/10/2022] Open
Abstract
Background Underserved ethnic minority women experience significant disparities in cervical cancer incidence and mortality, mainly due to lack of cervical cancer screening. Barriers to Pap smear screening include lack of knowledge, lack of health insurance and access, and cultural beliefs regarding disease prevention. In our previous SUCCESS trial, we demonstrated that HPV self-sampling delivered by a community health worker (CHW) is efficacious in circumventing these barriers. This approach increased screening uptake relative to navigation to Pap smear screening. SUCCESS trial participants, as well as our community partners, provided feedback that women may prefer the HPV self-sampler to be delivered through the mail, such that they would not need to schedule an appointment with the CHW. Thus, our current trial aims to elucidate the efficacy of the HPV self-sampling method when delivered via mail. Design We are conducting a randomized controlled trial among 600 Haitian, Hispanic, and African-American women from the South Florida communities of Little Haiti, Hialeah, and South Dade. Women between the ages of 30 and 65 years who have not had a Pap smear within the past 3 years are eligible for the study. Women are recruited by CHWs and complete a structured interview to assess multilevel determinants of cervical cancer risk. Women are then randomized to receive HPV self-sampling delivered by either the CHW (group 1) or via mail (group 2). The primary outcome is completion of HPV self-sampling within 6 months post enrollment. Discussion Our trial is among the first to examine the efficacy of the mailed HPV self-sampling approach. If found to be efficacious, this approach may represent a cost-effective strategy for cervical cancer screening within underserved and underscreened minority groups. Trial registration ClinicalTrials.gov, NCT02202109. Registered on 9 July 2014. Electronic supplementary material The online version of this article (doi:10.1186/s13063-016-1721-6) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Erin Kobetz
- Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Clinical Research Building, 1120 NW 14th Street, Room 610B, Miami, FL, 33136, USA. .,Department of Medicine, University of Miami Miller School of Medicine, 1120 NW 14th Street, Miami, FL, 33136, USA. .,Health Choice Network, 9064 NW 13th Terrace, Miami, FL, 33172, USA.
| | - Julia Seay
- Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Clinical Research Building, 1120 NW 14th Street, Room 610B, Miami, FL, 33136, USA.,Department of Medicine, University of Miami Miller School of Medicine, 1120 NW 14th Street, Miami, FL, 33136, USA
| | - Anthony Amofah
- Health Choice Network, 9064 NW 13th Terrace, Miami, FL, 33172, USA
| | - Larry Pierre
- Center for Haitian Studies, 8260 NE 2nd Avenue, Miami, FL, 33138, USA
| | - Jordan Baeker Bispo
- Department of Public Health Sciences, University of Miami Miller School of Medicine, 1120 NW 14th Street, Miami, FL, 33136, USA
| | - Dinah Trevil
- Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Clinical Research Building, 1120 NW 14th Street, Room 610B, Miami, FL, 33136, USA
| | - Martha Gonzalez
- Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Clinical Research Building, 1120 NW 14th Street, Room 610B, Miami, FL, 33136, USA
| | - Martine Poitevien
- Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Clinical Research Building, 1120 NW 14th Street, Room 610B, Miami, FL, 33136, USA
| | - Tulay Koru-Sengul
- Department of Public Health Sciences, University of Miami Miller School of Medicine, 1120 NW 14th Street, Miami, FL, 33136, USA
| | - Olveen Carrasquillo
- Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Clinical Research Building, 1120 NW 14th Street, Room 610B, Miami, FL, 33136, USA.,Department of Medicine, University of Miami Miller School of Medicine, 1120 NW 14th Street, Miami, FL, 33136, USA
| |
Collapse
|